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HIV eradication efforts have been unsuccessful due to virus persistence in cellular and 
tissue reservoirs. Recent evidence suggests that germinal centers (GCs) within lymph 
nodes (LN) contain a novel subset of regulatory T cells (TREGs), termed follicular 
regulatory T (TFR) cells. These cells control the magnitude and specificity of the GC 
response and like TREGs are essential for the maintenance of self-tolerance and immune 
homeostasis. However, the exact role of TFR cells in HIV infection and their contribution 
to viral control is not completely understood, possibly due to their low frequency, 
heterogeneity and more so, the difficulty in accessing human lymphoid tissue samples to 
fully study them.   
 
Thus, we set out to comprehensively investigate TFR cells in LN and peripheral blood 
(PB) samples, using a multifaceted approach including flow cytometry, MHC class II 
tetramers, immunofluorescence microscopy (IF), ELISA, digital droplet PCR and single-
cell RNA sequencing (SeqWell), in HIV-1 clade C infection. Furthermore, we aimed to 
determine the effect of very early treatment on the frequency and function of this cell 
subset.  
 
Overall, our studies contributed various notable findings to the field. Firstly, we were able 
to develop MHC class II tetramers, specific in our HIV-1 clade C setting, as a more 
sensitive method of identifying very low cell frequency antigen-specific CD4+ T cells 
without relying on function. Tetramers eliminate the bias associated with in vitro 
stimulation required for functional assays and the limitation associated with only 
detecting subsets of cells capable of secreting a cytokine. Notably, we used class II 
 xxiv 
tetramers to demonstrate that HIV-specific CD4+ T cell responses restricted to 
DRB1*11-Gag41 are associated with immune control of HIV-1 infection.  
 
We next focused on understanding the role of CD4+ regulatory cells during HIV-1 
infection. Firstly, we showed that TFR cell frequencies were significantly higher in LN 
compared to PB samples. Secondly, TFR are a phenotypically and transcriptionally 
distinct subset compared to regulatory T cells (TREGs) and T Follicular Helper cells 
(TFH). Thirdly, we were able to detect HIV-specific TFR using our newly synthesized 
MHC class II tetramers, and showed higher frequencies observed in LNs during untreated 
HIV infection. Fourthly, as measured by both flow cytometry and IF, most of TFR 
localized outside of the GC, with very early ART initiators displaying larger proportions 
of TFR within the GC. Lastly, TFR cells exhibited a potential suppressive functional 
capacity as they produced IL-10, which is a canonical suppressive cytokine and they were 
also positively associated with gp41 IgG antibodies titers. 
 
Overall, the data presented in this thesis highlights the advantage of MHC class II 
tetramers in evaluating HIV-specific CD4 + T cell responses in natural infections. More 
so, the results give important insights into regulatory cells within lymph nodes; their 
biology, function and their role in the setting of very ART initiation.
 1 
CHAPTER 1: INTRODUCTION 
 
 
1.1 The HIV/AIDS epidemic 
The first clinical observation of Acquired Immune Deficiency Syndrome (AIDS) was 
made in 1981 in the United States of America amongst injecting drug users and 
homosexual men with no known cause of weakened immunity. These individuals 
presented with symptoms of Pneumocystis pneumonia and Kaposi’s sarcoma, with both 
diseases having been previously reported as rare infections, occurring only in people with 
severely compromised immune systems (1-4). A few years later, the Human 
Immunodeficiency Virus (HIV), discovered in 1983, was isolated and identified as the 
pathogen responsible for AIDS. HIV infection quickly became established as a global 
pandemic (5). The disease is caused by two lentiviruses, human immune deficiency virus 
type 1 (HIV-1) and HIV-2 (6) and is closely related to Human T Lymphotropic Virus 
(HTLV) (7). AIDS is characterized by a marked reduction of CD4+ T cells and ultimately 
a failure of the immune system to contain virus replication, leading to increased 
susceptibility to opportunistic infections and malignancies and finally death (8). 
The origin of human infections traces back to multiple cross-species transmissions of 
simian immunodeficiency virus (SIV) from primates to humans (6). In humans it is 
primarily transmitted through sexual contact (most commonly heterosexual), exposure to 
HIV-contaminated needles, surgical items and bodily fluids or through vertical 
transmission from mother to child (9, 10). Since the clinical recognition of the disease, 
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HIV/AIDS has rapidly emerged as one of the world’s deadliest infectious diseases. An 
estimated total of 36.9 million people were reported to be living with HIV-infection 
globally at the end of 2017, with 66% living in sub-Saharan Africa (Figure 1.1) (11). In 
that same year, an estimated 1.8 million people became newly infected with HIV, and 
940 000 died of AIDS, including 110 000 children.  
Although there is still no cure for HIV-1 infection, the introduction and implementation 
of antiretroviral therapy (ART) from the mid-1990s onwards has proven to be successful 
in prolonging the lives of those infected, preventing new transmissions and reducing 
mortality and morbidity rates (12). This is evident in the reduction in AIDS-related deaths 
by 51% since the peak in 2004. Furthermore, the number of new infections has declined 
by 47% from 3.4 million in 1996 to 1.8 million in 2017. In addition, as at 2017, 59% 
(21.7 million) people living with HIV were accessing ART (11). However, despite these 
advances made in combating HIV, the pandemic is still a global health concern. The 
increasing evidence of resistance to currently available treatment regimens, together with 
limited accessibility of ART in resource-limited countries and adherence are ongoing 
issues making it difficult to bring the epidemic under control. Additionally, HIV has a 
high mutation rate which contributes to the development of resistance to treatment (13). 
Therefore, it is widely believed that a successful HIV vaccine would be the best weapon 





Figure 1.1 Global prevalence of HIV among adults aged 15-49 in 2017. Source: WHO 
(14). 
1.2 Clinical course of HIV-1 infection 
The natural history of HIV is well documented. It can be categorised as three distinct 
phases i.e. acute (primary) infection, asymptomatic phase and clinical AIDS-defining 
illness. The acute phase usually lasts a few months, followed by the early/clinically 
dormant phase that characteristically lasts for 3-10 years, and finally the characteristic 
immune collapse of AIDS (Figure 1.2) (15). Following HIV-1 infection, in the acute 
phase, HIV is detectable in the blood serum and plasma, but antibodies which is regularly 
used to diagnose infection have yet to form (16). HIV replication during the acute phase, 
usually results in high levels of viremia and shedding of the virus at mucosal sites. The 
onset of early virus-specific immune responses is coincident with a decrease in viremia 
(17, 18). Evidence in SIV-infected rhesus macaques indicate that resting memory CD4+ 
T cells expressing CCR5 are suggested to be the first cells infected. The virus 
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disseminates quickly into the lymphatic system and becomes detectable in local lymph 
nodes one week after infection (19). The virus spreads to various other anatomical sites 
after a week, with the gut-associated lymphoid tissue (GALT) being the most notable, 
with large numbers of CD4+ CCR5+ memory T cells residing within (20). 
 
The initial two weeks of infection is often referred to as the window period, with 
asymptomatic infection and undetectable plasma virus by standard methods of testing 
(21, 22). Since anti-HIV antibodies are usually undetectable during this window period, 
more sensitive qualitative and quantitative diagnostic assays, such as qualitative or 
quantitative HIV viral RNA detection or amplification methods are used for diagnosis 
and very early HIV-1 detection (23). Fourth generation serological tests developed in 
recent years that detect either antigens or antibodies have considerably reduced the 
window period down to five days after infection (24).  
 
Seroconversion follows the asymptomatic phase of virus replication and is denoted by 
the appearance of HIV-1 specific antibodies in plasma (25). The clinical stages of acute 
HIV-1 infection is defined by the step-by-step detection of antibodies and viral markers 
in the blood by different clinical assays. One of the most widely used system of 
classification is called Fiebig staging, which comprise of six sequential steps of defining 
acute HIV infection, based on detection of Gag p24 antigen and anti-HIV antibodies 
(Figure 1.3) (22).  
 
A clinical latency phase, also known as the chronic stage, follows the acute period.  It is 
at this point that viral and host factors merge to dictate a virologic set point (26). Towards 
 5 
the middle or end of this period, viral load begins to increase and CD4 count begins to 
decrease, usually signalling the progression of HIV symptomatic disease, thus leading to 
the eventual and full blown AIDS (26). The course of infection is influenced by various 
host and virus factors and is therefore characteristically different between individuals 
(27). Most individuals, following primary infection, would experience an extended 
clinical latency period, with progression to clinically noticeable disease or an AIDS 
defining illness occurring within eight to ten years. Untreated infection leads to 
progressive damage to the immune system and susceptibility to opportunistic infections; 
with impaired humoral responses, T cell activation, exhaustion and depletion of CD4+ T 
cells, chronic inflammation and changes in lymphoid tissue architecture (28, 29). This 
overall dysregulation can be decreased drastically with the administration of antiretroviral 





Figure 1.2 Stages of HIV infection from transmission to seroconversion and the immune 





Figure 1.3 Natural history and fiebig staging of acute HIV infection. Source: Fiebig et 
al., (22). 
1.3  Therapeutic strategies for HIV-1 infection 
1.3.1 Antiretroviral treatment 
 
Unprecedented efforts by various stakeholders have contributed to progressively turn 
HIV infection from an inevitably fatal condition into a chronic manageable disease, with 
the initiation of ARV drugs in the mid-1980s (30, 31). Standard antiretroviral treatment 
regimens have evolved from single ARVs to combinations of multiple drugs with 
different modes of action. The role of ART is to stop viral replication and restore immune 
function by inhibiting crucial HIV replication steps. Combination therapy rapidly 
suppresses the virus , minimizing drug resistance and limiting treatment failure (32).  
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The major goals of ART is to prevent the onset of AIDS and AIDS-related illnesses and 
to improve the quality of life. ART also prolongs the life expectancy of those infected 
and prevents further transmission to uninfected individuals. There are six different 
mechanistic classes of ARV agents currently approved by the US Food and Drug 
Administration (US-FDA) for the treatment of HIV infection are as follows (Figure 1.4): 
 
a. Nucleoside reverse transcriptase inhibitors (NRTIs): their mechanism of 
action is  reverse transcription inhibition. Nucleic acid analogues mimic the 
normal building blocks of DNA, preventing transcription of viral RNA to DNA 
(33). 
 
b. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): also target the 
reverse transcription step by binding to the RT at a site distant to the active site 
and therefore inducing a conformational change that alters the active site of the 
enzyme and limiting its activity (33). 
 
c.  Protease inhibitors (PIs): function by inhibiting the final maturation stages of 
HIV replication, resulting in the formation of immature and non-infective viral 
particles (33, 34). 
 
d. Integrase inhibitors (IIs): function by inhibiting the transfer reaction of the 
proviral strands into host chromosomal DNA during the integration step through 
binding of the metallic ions in the enzyme's active site (32, 35).  
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e. Fusion inhibitors (FIs): function by interfering with the HIV fusion step by 
competitively binding to the gp41 and preventing the conformational changes 
required for gp41 to complete the fusion process (36).  
 
f. Chemokine receptor antagonists (CRAs): also known as CCR5 antagonists, 





Figure 1.4 HIV life cycle: Targets for antiretroviral intervention. Approved drugs 
categorized according to their mechanism of action within the life cycle (39). 
 
1.3.2 Treatment of primary HIV-1 infection 
World Health Organization (WHO) has new recommendations that ART should be 
immediately initiated for individuals that test positive for HIV regardless of the CD4 
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count (40, 41). Previous guidelines stated that treatment be initiated at 500 CD4+ cells or 
fewer per mm3 of blood of HIV infected individuals and before that infected individuals 
had to have a CD4 count of below 250 cells/μl, or present with co-morbidities. The scale-
up of ART worldwide has resulted in significant reduction in AIDS-related deaths and 
has contributed to reduced HIV transmission rates (11).  
 
Since the introduction of the very first antiretroviral agents, the question of when 
treatment should be initiated has not been fully answered. There has been heightened 
interest on the benefits and risks of rapid initiation of ART soon after HIV diagnosis is 
confirmed. As alluded to earlier, international guidelines now recommend early treatment 
initiation due to emerging data showing the beneficial impact of early ART (42, 43). The 
effect of the timing of ART initiation on both clinical and microbiologic outcomes has 
been debatable in terms of the benefit of therapy and the associated short-and long term 
costs, effects of drug toxicity, development of resistance and adverse effects on quality 
of life due to the longer duration of ART (44). There have been numerous studies 
providing strong evidence that initiation of ART at a threshold of <350 cells/μl CD4+ T 
cell count improves survival and delays disease progression (45), with additional studies 
suggesting a reduction of the risk of AIDS-defining illnesses and/or death with ART 
initiation at <500 CD4+ T cells/μl (46), and most recently data from randomized studies 
indicating that ART initiation immediately after HIV diagnosis, irrespective of CD4+ T 
cell count results in significant reductions of morbidity and mortality (47, 48). Results 
from these trials led to strengthening of international recommendations of ART for all 
HIV-infected individuals.  
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Various studies evaluating ART during acute HIV infection have shown the beneficial 
effects on laboratory progression markers. The positive effects of early ART initiation, 
during the acute phase of HIV infection, include reduction of viremia (49), lower viral 
load set point (50), lower probability of transmission (15, 51, 52), and overall a reduced 
number of infected cells thus limiting the size of the pool of latently infected CD4+ T 
cells (53, 54). Additionally, preservation of HIV-specific immune responses have been 
observed following initiation of ART in the initial phase of infection, by preserving the 
ability to control viral replication and avoiding early destruction of CD4+ T cells (55).  
 
Despite having understood the overall immunological, virological and clinical benefits of 
early detection and treatment during acute HIV infection, it should be noted that diagnosis 
of acute HIV infection is quite challenging, with the clinical appearance in most cases 
being unspecific and resembling that of other viral infections (15).  
 
Our group is uniquely positioned to assess acute HIV infection and the effects of very 
early ART initiation because of our access to the Females Rising through Education, 
Support, and Health (FRESH) study in KwaZulu-Natal, South Africa (56). FRESH is an 
acute HIV infection cohort that has overcome the challenges of detection of HIV during 
Fiebig stage I. The study uses the approach of testing HIV uninfected individuals who are 
at high risk of infection, adhering to a frequent surveillance schedule, allowing for 
detection during acute HIV infection. A socioeconomic empowerment programme, 
designed to coincide with sampling before and after infection, is conducted alongside the 
basic science research. Investigation of the earliest immunological and virological events 
after HIV infection is essential for novel development of preventive vaccines as well as 
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for HIV cure research. In this thesis work, we utilized the FRESH cohort to obtain 
matched peripheral blood and lymph node samples to answer valuable questions 
surrounding the impact of very early ART initiation on HIV-specific CD4+ T cell 
responses.  
1.4 The need for an HIV cure 
 
With the major strides that have been made in improving life expectancy and overall 
quality of life, lifelong ART has major side effects which result in toxicity, malignancies, 
increased age-related diseases, chronic inflammation among others. Moreover, ART is 
not readily accessible and free to everyone especially in low and middle-income countries 
and therefore cumulative costs of therapy is also a major concern (57, 58). Therefore, it 
is crucial to explore novel interventions that can enable people to control the virus in the 
absence of therapy. These strategies would need to completely eliminate residual virus 
from sanctuary sites within the body, which include lymph nodes and the gastrointestinal 
tract, which have been shown to harbour HIV reservoirs and have suboptimal drug 
penetration (59-61). The search for a curative strategy for HIV is a goal that is of utmost 
importance, with this area now being defined as a key priority in HIV research (61, 62). 
 
It is important for the term “cure” to be well defined amongst the broader interested 
individuals i.e. people living with HIV, researchers and clinicians. The most favourable 
outcome would be to achieve a sterilizing cure, which would be complete eradication of 
replication-competent HIV within an individual. This however has proven extremely 
challenging with the current knowledge and technology. Therefore, a more practical 
outcome would be to achieve long-term remission, which is defined as the absence of 
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viral rebound after ART interruption for an undefined period of at least several years. The 
concept of remission is increasingly being described and utilized in the field of HIV 
research to indicate the overall goal of long-term undetectable viremia in the absence of 
ART (63-65). The idea of disease remission is already well established in medical settings 
and is known to denote improvement, albeit with some uncertainty (66).  
 
The primary barrier to a cure for HIV is the existence of a stable reservoir of silenced 
fully integrated HIV DNA in long-lived cellular reservoirs, which besides CD4+ T cells 
include cells of the monocyte-macrophage lineage, as well as hematopoietic progenitor 
cells (HPCs) amongst others (67). This small population of memory T cells that lack 
activation markers have been repeatedly isolated from peripheral blood despite durable, 
successful ART, and are found to harbour integrated HIV DNA that are capable of 
producing replication-competent virus. These cells have been shown to persist for many 
years, with little changes in their frequency despite prolonged therapy (59, 60, 67, 68). 
These cells are enriched in lymphoid tissues, particularly secondary lymph nodes (69), 
the spleen and mucosal surfaces (70). The viral rebound from these reservoirs upon 
treatment interruption represent the major challenge in achieving a cure for HIV. There 
have been a few encouraging cases over the years that indicate a cure and sustained HIV 
remission is possible in the absence of ART (Figure 1.5). Sustained periods of aviremia 
in the absence of therapy was achieved in an aggressively treated infant (The Mississippi 
Child) (71, 72) , in at least two individuals who have received allogeneic stem cell 
transplant (The Boston patients) (73), in adults who received several years of ART 
initiated soon after infection (The Visconti cohort) (65), and a teenager showing viral 
remission more than 12 years after ART interruption from the same group (74). But, the 
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most notable cure case is Timothy Ray Brown, most commonly known as the Berlin 
Patient, who received a stem cell transplant using donor stem cells that were homozygous 




Figure 1.5 Viral rebound following cessation of ART. Typical rebound usually occurs 
within 2-3 weeks. In some instances viral rebound has been significantly delayed in the 
setting of stem cell transplantation (Boston Patients) or very early ART in an infant (the 
Mississippi Child). In some individuals, long-term post-treatment control (PTC) off ART 
has been achieved. In these PTC, ART was nearly always initiated in acute infection and 
virus is usually detected at low levels in plasma. Timothy Brown (the Berlin Patient) 
remains the only HIV infected individual off  ART with no virus detected in blood or 
tissue. Source: Deeks et al., (61).  
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There are many elements that limit our ability to define the factors that would favour 
control off ART. These would include, dynamics of viral reservoirs as well as their size, 
cellular and anatomic locations. Furthermore, of particular importance is the limited 
knowledge on the impact of the timing of ART initiation on reservoirs and the 
immunologic and virologic factors that influence reservoir formation. Unless complete 
viral eradication is achieved, immune control through native responses or immune-based 
therapies will likely be necessary for maintaining remission after ART interruption (76). 
Many questions remain unanswered in the setting of HIV persistence on ART. These 
include the antigen-specificity during ART and if this is similar to untreated disease, the 
CD4+ T cell populations that HIV persist in and the changes in distribution and frequency 
of these cells over time. Ultimately, it would be important to discover non-virologic 
biomarkers that detect with high sensitivity the persistence of HIV in an infected 
individual as well as identify mechanisms of enhancing the capacity of the immune 
system to clear or control HIV. Immune-based therapeutics that are informed by the 
immunology of HIV persistence are likely be a major focus of cure research in the future 
(77). 
1.5 Host immune responses to HIV infection 
 
HIV infection is associated with robust immune responses. In untreated HIV-1 infection, 
a partial immune response is essential to prevent disease progression to full blown AIDS. 
Both the innate and adaptive immune systems (which comprise of humoral and T-cell 
dependent responses) are required to suppress HIV-1 infection (78).  
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HIV-specific T cell responses  play an important role in the decline of viral load during 
primary infection as well as in being able to influence viral load set point (79-81). The 
role of cytotoxic CD8+ T cells (CTL) has been well established in immune mediated 
control of HIV. One of the key observations arguing for the role of CTLs in the initial 
control of virus replication is the temporal association between the emergence of CD8+ 
T cells and the rapid decrease in viral load during the acute phase of viral replication (82-
84). The loss of protective HIV-specific CD8+ T cell responses has been associated with 
a swift progression to full blown AIDS (85), with additional evidence in rhesus macaque 
models in SIV infection where depletion of CD8+ T cells resulted in a subsequent rise in 
SIV viral load and progression to disease (84, 86, 87). Furthermore, immune selection 
pressure and the detection of viral escape mutations in CTL-targeted epitopes further 
demonstrated the important role of CD8+ T cells in mounting a strong immune response 
against the virus (88).  
 
The progressive dysfunction and loss of HIV-specific CD8+ T cells have been implicated 
in increasing viral load and disease progression over time, together with the ongoing loss 
of CD4+ T cells. Other key attributes of CD8+ T cells, apart from the cytolytic activity, 
include polyfunctionality and functional avidity. The ability of CD8+ T cells to release a 
mixture of cytokines and chemokines in tandem have been shown to enhance cytolytic 
activity (89). Interestingly, polyfunctional CD8+ T cells have been shown to be elevated 
in a rare group of HIV positive individuals who maintain undetectable viral loads in the 
absence of any treatment, commonly referred to as elite controllers (90). 
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Host genetic effects and MHC class I molecules have also been widely studied, with a 
strong association between the rate of disease progression and the HLA class I alleles 
being demonstrated. The expression of particular HLA class I alleles restricting HIV-
specific CD8+ T cell responses are associated with different clinical outcomes. Various 
alleles such as HLA- B*57 or B*27 being referred to as ‘protective’ alleles, whilst the 
accelerated onset of AIDS is associated with ‘risk’ alleles such as HLA-B*35. Overall, 
strong associations between HLA class I expression and viral control indicate an 
important role for HLA class I-restricted CD8+ T cells in the setting of HIV-1 infection 
(91). 
 
HIV-specific CD8+ T cells have been studied in great detail, with various studies 
elucidating the host genetic determinants  and antiviral effects of HIV-specific CTLs (92-
94). However, very little is known about the role and contribution of CD4+ T cells to 
immune mediated control of HIV. Amongst the reasons for the paucity of studies on HIV-
specific CD4+ T cells and their contribution to viral control include; firstly, CD4+ T cells 
are the primary targets of HIV-1 infection (95) , secondly, unlike CD8+ T cells, CD4+ T 
cells circulate at very low frequencies, mostly below the sensitivity threshold of most 
current assays (20, 96).  
 
The main function of HIV-specific CD4+ T helper cells is to help B cell and CD8+ T cell 
responses. For instance, CD4 helper cells have been shown to play an important role in 
generating long-lasting, robust antiviral memory of CD8+ T cells (97, 98). While antigen-
specific CD8+ T cells have the ability to be primed without CD4+ T cell assistance, 
subsequent expansion following the re-encountering of the antigen is inefficient without 
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CD4+ T cell help (99-101). The advanced loss of general CD4+ T cells and HIV-specific 
CD4+ T cells during HIV infection has been assumed to lead to the dysfunction of virus-
specific CD8+ T cells and the unsuccessful suppression of these chronic viral infections 
(102-104). More recently HIV-specific CD4+ T cell responses and have been shown to  
play an important role in helping B cells responses. CD4+ T cells are necessary to 
generate and maintain humoral immune responses by providing help to antigen-specific 
B cells for the production of antibodies (105, 106). Furthermore, CD4+ T cell responses 
are thought to provide superior helper activity to Env-specific B cells, promoting their 
differentiation, maturation, and secretion of neutralizing antibodies (105). 
 
Currently virus-specific CD4+ T cell responses in HIV-1 infection are poorly defined and 
there is a lack of information on HLA class II restriction of HIV-specific responses. As 
previously alluded to, HLA class I alleles have been characterized, with their genetic 
association with HIV control being well defined (107, 108). However, recent studies have 
suggested that HLA class II alleles may also have an effect on the control of HIV (109-
111). Several HLA class II DRB1*13 alleles and the DRB1*13-DQB1*06 haplotype 
have been shown to bestow a degree of protection in terms of HIV disease outcome. 
Studies have shown that individuals expressing theses alleles, display the strongest HIV-
specific CD4+ T cell responses (112). The DRB1*1303 allele in particular has been 
associated with reduced viral loads in both subtype B and C populations (109, 112). The 
DRB1*13 allele has also been shown to confer protection in other infections, particularly 
hepatitis B, where presence of this allele has been associated with a greater frequency of 
clearance as well as better clinical outcome (109). Although not conclusive, the finding 
of strong associations between class II HLA alleles and breadth and magnitude of CD4+ 
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T cell responses re-iterates the important role that CD4+ T cells have in immune mediated 
control of HIV. 
 
The identification of the specificities and efficacies of HIV-specific CD4+ T cell 
responses is likely to be vital for HIV vaccine design. Indeed, it will be important to 
identify which HIV-specific CD4+ T cells are induced in natural HIV infection in order 
to successfully augment the efficacy of these responses in future vaccine and cure 
strategies. 
1.6 CD4+ T helper cell subsets  
 
T helper (Th) cells play important roles in coordinating adaptive immune responses. They 
carry out functions principally through the secretion of cytokines and chemokines that 
activate and/or recruit other immune cells including B cells, CD8+ T cells, macrophages 
and other effector cells (113). The complex biology and diversity in functions of CD4+ 
T cells are determined by their cytokine secretion and their tissue locations (Figure 1.6). 
Initially, CD4+ T cells were divided into two subsets by Mosmann et al., in 1986 (114), 
Th1 and Th2, which respectively produced the signature cytokines interferon (IFN)-g and 
interleukin (IL)-4 and IL-13. Th1 cells are known to promote cytotoxic effector functions 
of natural killer (NK) cells, CD8+ T cells and macrophages and mediate immune 
responses against intracellular pathogens such as viruses, intracellular bacteria and 
protozoan parasites (113). This subset also promotes antibody-dependent cell-mediated 
cytotoxicity (ADCC) by supporting B cell production of IgG1 in humans (113). Th2 cells 
are important for the clearance of extracellular pathogens such as helminths and also 
promote humoral immunity, mediated by B cell-produced IgG4 and IgE in humans (113, 
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115). As new technologies have emerged, various other subsets of CD4+ T cells have 
arose to add to the classic Th1 and Th2. Each of the subsets are identified and 
characterized by their lineage-defining transcription factor or the migration markers they 
express (116, 117). Besides Th1 and Th2, other well defined CD4+ T cell subsets include; 
Th9, Th17, Th22, TFH and TREG. The various lineages are dependent on the expression 
of transcription factors, effector cytokines, and chemokine receptors (Figure 1.6) (113, 
118). Th9 cells, which produce anti-inflammatory cytokines, IL-10 and IL-9 provide 
defences against nematodes (119, 120) and the Th17 facilitate antimicrobial immunity 
and protection at mucocutaneous sites (121). TFH cells specialize in helping B cell 
responses, while TREGs regulate immune responses and prevent autoimmunity (119, 
122, 123). 
 
It is important to note that most of CD4+ T cells reside within the gastrointestinal (GI) 






Figure 1.6 T helper cell lineage development and functions. T helper cell lineages can 
be divided into Th1, Th2, Th9, Th17, Treg, Tfh and Th22 cells that are involved in distinct 
immune functions (118). 
1.7 T regulatory  (TREG) cells 
 
Regulatory T (TREGs) cells are a subset of circulating CD4+ T cells with suppressive 
properties implicated in immune tolerance (125), auto-immune diseases, cancer, 
transplantation, maternal-fetal tolerance and inflammation induced by chronic pathogens 
(126, 127). They are phenotypically defined minimally as CD4+CD25+FOXP3+, with 
their development, maintenance and function dependent on the expression of the master 
transcription factor FOXP3 (forkhead box P3) (128). Natural Tregs (nTreg) are generated 
in the thymus (129) and are detected in peripheral blood, mucosal and lymphoid tissues 
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where they prevent autoimmunity and decrease immune activation (130). Adaptive or 
induced Tregs (iTregs) develop in the periphery from mainstream peripheral ab T cells 
using self (131) or foreign antigens (132). These are essential in mucosal immune 
tolerance and during normal homeostasis of the gut. There have been many conflicting 
reports of on the role of TREGs in HIV infection, with many considering these cells a 
double-edged sword (Figure 1.7) (133). The effects of TREG expansion, which has been 
observed in HIV infection, could be either beneficial, by suppressing generalized T-cell 
activation, or detrimental, by weakening HIV-specific responses and thus contributing to 
viral persistence (133). The mechanisms through which TREGs carry out their function 
are not fully understood, however studies have shown that TREG action is through the 
production of bioactive molecules, such as IL-10 and TGF-b as well as through cell-cell 
contact mediated regulation via the high affinity TCR and other co-stimulatory molecules 
such as CTLA-4; glucocorticoid-induced tumor necrosis factor-related receptor (GITR) 
and cytolytic activity (134, 135).   
Most of the studies on TREGs have been in peripheral blood, despite the fact that HIV is 
a disease primarily of lymphatic tissues, with most viral replication occurring in CD4+ T 
cells within these compartments (136). It should be noted that peripheral blood only 
contains 2% of the total CD4+ T cell population in the body, with most of these being 
effector memory cells in transit. The impact of HIV replication is most reflective on the 
populations residing within secondary lymphoid organs (136).  
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Figure 1.7 Dual role of TREGs in HIV infection. The presence and expansion of 
TREGs observed during HIV infection could be either beneficial or detrimental to the 
host immune system (133).  
1.8 T follicular regulatory cells 
 
As alluded to earlier, CD4+ T cells are also critical in both supporting and regulating the 
efficacy and longevity of humoral immune responses. T cells are known to migrate to 
germinal centres (GC) and B-cell-enriched follicles within secondary lymphoid 
compartments in order to provide help to B cells. Recent evidence suggests that B-cell 
follicles contain a novel subset of TREGs, termed follicular regulatory T cells (TFR) 
(137, 138). The transcriptional pattern of TFR overlaps with follicular T helper cells 
(TFH). TFH are critical initiators of GC responses, however studies have shown that 
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although an expansion of TFH cells is observed in HIV infection, this expansion does not 
necessarily correlate with improved GC responses. The factors driving this dysregulation 
remain unclear. One potential mechanism could be the presence of high frequencies of 
TFR cells in the lymph node (139). Like TFH, TFR cells express high levels of the 
follicle-homing chemokine receptor 5 (CXCR5), programmed cell death protein-1 (PD-
1) and inducible T cell co-stimulator (ICOS) (140). TFR also express the transcription 
factor B cell lymphoma 6 (Bcl6), which is a canonical TFH transcription factor, albeit at 
lower levels. However, several studies have shown that TFR cells primarily originate 
from natural FOXP3+ Treg precursors (141, 142). TFR cells are also different from TFH 
in that they express FOXP3 and BLIMP-1.  
 
1.8.1 Differentiation and regulation of TFR cells 
 
Antigen exposure triggers the differentiation of TFR cells in a dendritic cell (DC)-
dependant manner, which are found in the spleen, lymph nodes or other lymphoid organs 
such as Peyer’s patches (143, 144). Like TFH, TFR cells are thought to have two phases 
of differentiation: firstly, the imprinting of the TFR program after interaction with DCs, 
and the second phase where the TFR signature is strengthened upon interaction with B 
cells within the follicle/germinal centre (140). The mTorc1 pathway has recently been 
shown to be a key regulator of TFR cells. The mTorc1 complex is essential in regulating 
the conversion of TREGs to TFR cells, which is potentially mediated through a Stat3-
Tcf-1 – Bcl6 pathway  (Figure 1.8) (145, 146). The precise antigens and signals that 
TREGs respond to in order to become TFR cells is not well understood, with studies 
indicating that TFR cells respond more strongly to self-antigens than foreign antigens, 
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with further work showing TFR cells develop in a polyclonal and antigen-independent 
manner from TREGs (144, 147). Much work remains to fully understand the specific 
genes and pathways that regulate human TFR cells. 
 
 
Figure 1.8 Cell surface receptors and transcription factors involved in TFR cell 
differentiation and function. Red receptors are downregulated and green receptors are 
upregulated during TFR cell differentiation (148).  
1.9 T follicular regulatory cells and HIV infection  
1.9.1 Suppressive functions of TFR cells 
TFR have been mainly described in literature as suppressors of the GC reaction and 
antibody (Ab) response, shown to repress proliferation of TFH cells and GC B cells, thus 
limiting the generation of Ab-secreting cells and overall Ab responses (Figure 1.9). In 
vitro studies have shown that TFR can suppress proliferation and cytokine production of 
TFH cells as well as proliferation and Ig secretion of B cells, similarly to what has been 
described for TREGs (143, 147, 149-151). The precise mechanisms that is used by TFR 
to negatively regulate the GC reaction is still unknown. A major disadvantage is the fact 
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that in vitro studies cannot mimic the in vivo environment of the GC reaction and cannot 
be used to analyse affinity selection of GC B cells.  
 
1.9.2 “Helper” functions of TFR cells 
Although TFR are generally described as suppressor cells, there have been a few reports 
that suggest that under certain special circumstances, TFR can be deemed as having a 
“helper” function. Linterman et al., in 2009 (152), was the first to show that TFR display 
a vital “helper” role by helping TFH in selecting high-affinity Ag-specific B cell clones. 
In a murine study by Wu et al., (153), loss of TFR cells led to a significant decrease in 
IgG response and consistent with previous work, TFR cells were required to produce 
highest affinity Ag-specific Abs. Another murine study by Laidlaw et al., (154) analysed 
the GC and Ab response in lymphocytic choriomeninigitis virus (LCMV). Their results 
showed that IL-10 drives the growth of GCs. In these studies, they observed a decrease 
in GC B cells numbers and LCMV-specific Ab in the absence of IL-10 producing TFR 
cells. Overall these studies point towards a major role of TFR in maintaining the GC 
reaction and acting as “helper” cells. This seemingly paradoxical role of TFRs warrants 
further detailed and mechanistic investigation. 
 
There are many unanswered questions surrounding this newly identified subset of T 
suppressor cell. TFR cells have been analysed in a very small number of infectious and 
immunological disease models and testing the function of TFRs in various disease states 
is an important research area. A major consideration as the field progresses would be to 
determine the mechanisms and under which conditions TFR are able to switch between 
helper and suppressor functions within GCs. The signals that drive TFR responses and 
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the antigens that they recognize is also a very much unknown. Much work remains to 
fully understand the role of TFRs in humoral immune response in particular and in the 
overall immune response to infection. Therefore, this thesis is focused on understanding 
how this cell subset modulates induction of adaptive immune responses. 
 
 
Figure 1.9 Follicular helper T (Tfh) and T follicular regulatory (Tfr) cells both act 
in the germinal centre (GC) to regulate the generation of antigen (Ag)-specific 
antibody-secreting cells (148).  
1.9.3 TFR and HIV persistence  
 
HIV-1 replication is mainly concentrated in TFH cells within B cell follicles of secondary 
lymphoid tissues during chronic asymptomatic disease (155-157). Virus replication 
within these sites could be attributed to various factors including paucity of virus-specific 
CTL (156, 158), heightened permissivity of TFH (157) and the presence of highly 
infectious virions on follicular dendritic cells (FDC) (159). TFH, within secondary 
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lymphoid follicles, have been shown to be highly susceptible to HIV infection (160), but, 
there is very little evidence on TFR susceptibility to HIV-1 infection. A recent study by 
Miller et al., in 2017 (161), was the first to show in tonsil cells from children at low risk 
of HIV-1 infection, that TFR were more permissive to R5-tropic HIV-1 infection ex vivo 
than TFH and extra-follicular CD4+ T cells. TFR were more susceptible to R5 viral fusion 
than other cells and expressed the highest levels of CCR5 and CD4. Furthermore, this 
study showed in lymph node (LN) cells from asymptomatic HIV-1-infected humans, TFR 
harboured  the highest concentrations of HIV-1 RNA (161) . The authors suggested that 
from their previous work demonstrating that TFR were more resistant to apoptosis than 
TFH in ex vivo  HIV-1 infection (139) and the current work on TFR permissivity, it 
seemed likely that TFR and TREGs may be more resistant than other cells to cell death, 
and able to survive despite HIV infection and therefore contribute to the latent viral 
reservoir in ART-treated patients. Further work on the establishment and maintenance of 
latent infection in TFR and TREGs is therefore warranted and could lead to new HIV 
cure strategies. 
1.10 Appropriate tools to investigate HIV-specific CD4+ T cells 
 
Antigen (Ag)- specific T cells play a crucial role in mediating specific immune responses 
as well as in the formation of immunological memory. Therefore, detailed information 
about their frequencies, phenotypes, and functional capacities is necessary to estimate the 
specific immune status of an individual, to understand the mechanisms of protective 
immunity or immunopathology and to predict immune protection or diagnose immune-
related diseases (162). Evaluating antigen-specific T cells and their effector functions is 
vital to understanding overall T cell immunity in terms of assessing the effectiveness of 
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specific immune therapies (163). However, because of the low frequency at which these 
antigen-specific T cells occur in peripheral blood and lymphoid tissue, consistent and 
reliable measurement of T cell immunity is a major challenge. Commonly used assays to 
measure HIV-specific CD4+ T cells include the interferon (IFN)-γ ELISPOT, tetramer-
staining for common HLA-restricted epitopes and intracellular cytokine staining (ICS) 
measured by flow cytometry. The ELISPOT is a rapid and cost-effective method used in 
the large-scale detection and mapping of T cell responses. One of the limitations of the 
assay is that it works under the assumption that all HIV-specific CD8- or CD4+ T cells 
are identifiable by their ability to secrete IFN-γ post peptide stimulation. However, some 
antigen-specific cells do not readily produce IFN-γ and are therefore more likely to be 
missed by this assay.   
 
MHC class II tetramers have emerged as an important tool for characterization of the 
specificity and phenotype of CD4+ T cell immune responses, useful in a large variety of 
disease and vaccine studies (164). The analysis of Ag-specific T cells through the use of 
soluble MHC-peptide ligands that engage the abTCR was originally developed for MHC 
class I recognition in the context of CD8+ T cells (165, 166). In recent years, similar 
approaches have been used for MHC Class II recognition of CD4+ T cells for various 
antigens. However, CD4+ T cell recognition by MHC class II tetramers has had several 
constraints because of numerous factors which include; firstly, difficulty in producing 
class II MHC-based reagents due to folding conditions that need to be optimized 
individually for species and allotype. Secondly, low frequency of CD4+ T cells of interest 
in many biological contexts; which would require expansion or enrichment prior to 
detection by tetramers. And lastly, complications caused by low T-cell receptor (TCR)-
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MHC avidity; with some CD4+ T cells having too weak MHC-TCR affinity to support 
tetramer binding (167).  
 
The major limitation for using tetramers is the requirement to have prior knowledge of 
the specific peptide-MHC components involved in the recognition events being studied, 
because these are necessary to construct the tetramer reagents. The antigenic epitope has 
to be well characterized i.e. a defined peptide restricted to a particular MHC haplotype 
(162) .  
 
The initial part of this thesis therefore focused on developing the appropriate tools i.e. 
MHC class II tetramers for the analysis of antigen-specific CD4+ T cell populations 
within lymph nodes and peripheral blood in HIV-1 clade C infection. This tool, which 
provides information on cell frequency and specificity was used in conjunction with other 
immunological techniques to elucidate the role of helper and immunoregulatory cells 
within these two compartments.  
1.11 Thesis outline 
 
Increasing evidence suggests that virus-specific CD4+ T cells contribute to immune-
mediated control of clade B HIV-1 infection. Yet, there is very little known about the role 
of HIV-specific CD4+ T cells in immune mediated control of HIV-1 clade C infection, 
which is responsible for majority of HIV infections worldwide (168). Specifically, CD4+ 
T regulatory cells have been shown to be important during various chronic infections, 
including HIV, but little is known about their biology and function during HIV-1 clade C 
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infection. Furthermore, the exact role of regulatory cells during HIV-1 infection remains 
controversial, with both beneficial and detrimental roles having been described (133, 169, 
170). Regulatory cells have been shown to be beneficial because they suppress chronic 
immune activation and downregulate CD4+ T cells, thereby contributing to subsequent 
control of viral replication (169). But, they could also be  detrimental by inhibiting anti-
HIV immune responses, therefore promoting HIV persistence (171). Poor understanding 
of the role of TREGs in HIV pathogenesis is probably due to a number of reasons 
including but not limited to the shortage of tools to properly characterize these low 
frequency cells. Currently, developing assays that can fully quantify all the relevant 
epitope specific CD4+ T cell responses remains a major challenge in natural HIV 
infection and vaccine studies because of the tremendous complexity of CD4+ T cell 
biology.  
 
This study focused on understanding the role of HIV-specific immunoregulatory cells in 
lymphoid tissue and peripheral blood, particularly during early HIV infection, where 
these cells are more likely to influence the evolution of adaptive immune responses. The 
improved elucidation of HIV-specific CD4+ T cell responses and enhanced 
understanding of how regulatory cells may promote the generation of protective CD8+ T 
cell and B cell responses or mediate a direct antiviral role is highly relevant for future 
HIV vaccine design. Understanding the mechanisms by which CD4+ T regulatory cells 
exert their influence is an important research area with broad implications for the 




We chose to investigate the role of HIV-specific CD4+ T cells in HIV pathogenesis 
because our access to a primary HIV infection cohort (FRESH) that identifies individuals 
with “hyperacute” HIV infection and treats them at the onset of plasma viremia, with 
some being treated with plasma viral loads less than 1000 RNA copies/ml (56). In 
addition, our group has established protocols for excisional lymph node biopsies, cell 
sorting, multicolor immunofluorescence microscopy and class II tetramer technology. All 
these resources uniquely position us to effectively carry out detailed characterizations of 
CD4+ T helper and regulatory cells in HIV-1 clade C infection. 
 
Goal of study 
 
The overall goal of the study was to comprehensively characterize antigen-specific CD4+ 
T cells in peripheral blood and lymphoid tissue in HIV-1 clade C infection in KwaZulu-
Natal, South Africa. In particular, we sought to examine how regulatory CD4+ T cell 
subsets alter helper T cell frequency and function in the lymph nodes and how this 




Antigen-specific CD4+T cell immunoregulatory cells present in secondary lymphoid 




1. Develop class II tetramers to interrogate low frequency HIV-specific CD4+ T cells in  
HIV-1 clade C infection. 
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2. Phenotypically and functionally characterize antigen-specific CD4+ T cells in the 
immune regulation of HIV-1 within lymph nodes and peripheral blood. 
 
3. Determine the effect of early treatment on the frequency and function of regulatory 
CD4+ T cell populations in lymph nodes and peripheral blood. 
 
Chapter 1 is the introduction and provides an overview of relevant literature. 
 
Chapter 2 describes MHC class II tetramers designed to characterize Gag-specific CD4+ 
T cell responses in HIV-1 clade C infection.   
 
Chapter 3 defines the phenotype, transcriptional signature and antigen-specificity of 
CD4+ helper and regulatory T cell subsets within lymph nodes and peripheral blood using 
flow cytometry, single cell RNA-sequencing and MHC class II tetramers.  
 
Chapter 4 assesses changes in regulatory T cell frequencies within the lymph node in 
terms of localization and function, particularly in the setting of early antiretroviral therapy 
initiation, using flow cytometry, immunofluorescence microscopy, droplet digital PCR 
and ELISA. 
 
Chapter 5 details the overall implications and future research directions of the research 




Chapter 2 Overview 
 
As alluded to in our literature review, collective evidence suggests that virus-specific 
CD4+ T cells contribute to immune-mediated control of HIV-1 infection. Due to the low 
frequency of these cells, there is increased difficulty in measuring antigen-specific CD4+ 
T cells without prior manipulation, which massively alters their phenotypic and 
functional properties. Furthermore, only a small fraction of HIV-specific CD4+ T cell 
responses have been identified, with many studies relying solely on measuring IFN-γ as 
a readout for CD4+ T cell function. Having noted the complexity of these cells, it is 
evident that this would be an inaccurate representation of CD4+ T cell responses in the 
setting of HIV infection. With MHC class II tetramer technology now advancing, more 
studies are using this method of directly detecting antigen-specific CD4+ T cells without 
relying on function.  
 
In Chapter 2, we present a study conducted to develop the appropriate tools, i.e. MHC 
class II tetramers to better understand the role of HIV-specific CD4+ T cell responses in 
HIV control and disease progression.  
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Immune control of viral infections is heavily dependent on helper CD4+ T cell function. 
However, understanding the contribution of HIV-specific CD4+ T cell responses to 
immune protection against HIV-1, particularly in clade C infection remains incomplete.  
Recently, MHC class II tetramers have emerged as a powerful tool for interrogating 
antigen specific CD4+ T cells without relying on effector functions. Here, we defined the 
MHC class II alleles for immunodominant Gag CD4+ T cell epitopes in clade C virus 
infection, constructed MHC class II tetramers, and then used these to define the 
magnitude, function, and relation to viral load of HIV-specific CD4+ T cell responses in 
a cohort of untreated HIV clade C infected persons. We observed significantly higher 
frequencies of MHC class II tetramer+ CD4+ T cells in HIV controllers compared to 
progressors (p=0.0001) and these expanded Gag-specific CD4+ T cells in HIV controllers 
showed higher expression of the cytolytic proteins, Granzymes A and B. Importantly, 
targeting of the immunodominant Gag41 peptide in the context of HLA class II 
DRB1*1101 was associated with HIV control (r=-0.5, p=0.02). These data identify an 
association between HIV-specific CD4+ T cell targeting of immunodominant Gag 
epitopes and immune control, particularly the contribution of a single class II MHC-
peptide complex to the immune response against HIV-1 infection. Furthermore, these 
results highlight the advantage of class II tetramers in evaluating HIV-specific CD4+ T 





Increasing evidence suggests that virus-specific CD4+ T cells contribute to immune-
mediated control of clade B HIV-1 infection. Yet, there remains a relative paucity of data 
regarding the role of HIV-specific CD4+ T cells in shaping adaptive immune responses 
in clade C infection, which is responsible for majority of HIV infections worldwide. 
Understanding the contribution of HIV-specific CD4+ T cell responses in clade C 
infection is particularly important for developing vaccines that would be efficacious in 
sub-Saharan Africa, where clade C infection is dominant. Here, we employed MHC class 
II tetramers designed to immunodominant Gag epitopes and used them to characterize 
CD4+ T cell responses in HIV-1 clade C infection.  Our results demonstrate an association 
between the frequency of HIV-specific CD4+ T cell responses targeting an 
immunodominant DRB1*11-Gag41 complex and HIV viral control, highlighting the 
important contribution of a single class II MHC-peptide complex to the immune response 
against HIV-1 infections. 
2.3 Introduction 
 
Detailed characterization of immune cells that contribute to suppression of HIV 
replication is critical to both vaccine design and therapeutic approaches. Although both 
CD4+ and CD8+ T cells mediate cellular immune responses to HIV, most research efforts 
have focused on understanding the role of CD8+ T cells. In contrast, the role of CD4+ T 
cells is less well defined. CD4+ T cells contribute to immune control of many viral 
infections (1-6), implying that they may be similarly important for HIV immunity. 
Indeed, recent studies in HIV clade B infection have highlighted the important role of 
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HIV-specific CD4+ T cells as effectors of viral immunity (7, 8), in addition to being 
orchestrators of CD8+ T cell and B cell responses via helper signals (9). 
 
Although CD4+ T cell responses remain relatively understudied, emerging evidence 
suggests that they play a more active role in controlling HIV disease progression. A recent 
SIV study provided the first direct evidence of CD4+ T cell driven escape mutation. They 
identified a unique post-breakthrough mutation in the Gag region only targeted by CD4 
responses, which abrogated CD4+ T cell recognition (10). In humans indirect evidence 
generated by a computational approach identified HLA class II associated 
polymorphisms and linked predicted epitopes within adaptation sites to CD4+ T cell 
driven immune escape (11). Furthermore, recent studies conducted in clade B HIV 
infection in predominantly Caucasian populations showed that targeting Gag by CD4+ T 
cell responses restricted by some HLA-DRB1 alleles such as DRB1*15:02, 13:01 and 
DQB*:06 was associated with low viremia whereas CD4 responses restricted by 
DRB1*03:01 allele were linked to high viremia. The plausible explanation for the 
difference was that DRB1 alleles associated with low viremia had the capacity to present 
multiple epitopes at low functional avidity compared to alleles associated with high 
viremia (12-14). Taken together, these data underscore the impact of HIV-specific CD4+ 
T cell responses on the control of HIV replication.  
 
In contrast to these studies in clade B virus infection, much less is known about the role 
of CD4+ T cell responses in clade C HIV infection. Improved understanding of immune 
responses to clade C is particularly important for developing vaccines that would be 
efficacious in sub-Saharan Africa, where subtype C viruses which account for more than 
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50% of infections globally, are most dominant (15). A few clade C studies have identified 
immunodominant class II restricted CD4+ T cell epitopes, but the restricting alleles for 
these responses remain unknown (16, 17). The lack of knowledge about restricting alleles 
has made it difficult to synthesize class II tetramers that could be used to conduct more 
comprehensive CD4+ T cell studies without relying on specific effector functions. Most 
clade C studies have used IFN-γ intracellular cytokine staining (ICS) or ELISPOT assays 
to study CD4+ T cell responses (17). This approach is limited in scope because it can only 
detect IFN-γ secreting CD4+ T cell responses and is therefore more likely to miss other 
CD4+ T cell subsets such as Th-2, Th-17, T follicular helper cells and regulatory T cells 
that are defined by different signature cytokines. 
 
To investigate if virus-specific CD4+ T cells play an active antiviral role in the 
pathogenesis of clade C HIV infection, we first screened the entire HIV-1 clade C 
proteome for immunodominant HIV-specific CD4+ T cell epitopes and performed class 
II restriction studies to identify the most frequent class II DRB-1 alleles in an initially 
untreated, predominantly Zulu/Xhosa ethnic study population in a clade C endemic 
region. The screening data were used to synthesize MHC class II tetramers to the most 
immunodominant CD4+ T cell epitopes. The tetramers were then used to thoroughly 
examine the frequency and function of HIV-specific CD4+ T cell responses during 
chronic untreated HIV-1 clade C infection. Our data demonstrate that the frequency of 
immunodominant Gag-specific CD4+ T cells as measured by tetramers is inversely 
associated with contemporaneous viral load. These data highlight the important 
contribution of HLA class II-restricted epitope-specific CD4+ T cells to the immune 
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response against HIV-1 clade C infection and indicate that MHC class II tetramers are a 
sensitive tool for interrogating HIV-specific CD4+ T cells responses in natural infections.  
2.4 Materials and Methods 
2.4.1 Cohort characteristics 
 
A total of 80 subjects, chronically infected with HIV-1 clade C (76.3% female, n=61 and 
23.8% male, n=19) from the local Zulu/Xhosa population recruited as part of the 
Sinikithemba cohort (18) in Durban, South Africa, were studied. The Biomedical 
Research Ethics (BREC) of the University of KwaZulu-Natal and the institutional review 
board (IRB) of Massachusetts General Hospital approved this study. All study 
participants were antiretroviral naïve at the time of enrollment. Socio-demographic 
characteristics, plasma viral load measurements, and CD4+ T cell counts were obtained at 
baseline. Follow-up CD4+ T cell counts, and plasma viral load measurements were 
performed at 3-month and 6-month intervals. Individuals recruited in this study were 
stratified into two major groups: 34 HIV controllers defined here as individuals who 
maintained lower viral loads of <2,000 HIV RNA copies/ml for >1 year and 46 HIV 
chronic progressors (viral loads of >2000 HIV RNA copies/ml) based on 
contemporaneous viral load (Table 1). HLA-DRB1 typing was performed for all 
participants, as described (16). Cryopreserved peripheral blood mononuclear cells 
(PBMCs) samples from each individual were utilized for all assays. An initial number of 
72 participants were screened for HIV-specific CD4+ T cell responses using the ELISPOT 
assay. Individuals that made a CD4+ response were then screened using the HLA 
restriction assay to determine restricting alleles and epitopes. For additional comparison 
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between controllers and progressors, an additional 8 individuals that were not utilized in 
the initial screening were added to the data set. Hence, the total number of 80 participants 
in the study (Table 1). MHC class II tetramers were synthesized and tested in 
approximately one quarter (21/80) of study subjects in this clade C infection cohort who 
expressed the matching HLA class II DRB1 alleles. 
 
2.4.2 CD8+ T cell depletion and modified IFN-γ Elispot Assay 
 
A modified IFN-γ ELISPOT assay was used to screen all chronically infected subjects. 
Cryopreserved PBMCs were thawed and CD8+ T cells were depleted using Miltenyi 
MACS CD8 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany). The initial 
screening was carried out using a “megamatrix” approach (19, 20) using clade C 
consensus HIV-1 peptides custom-produced at the Massachusetts General Hospital Core 
facility. The megamatrix involved the use of 410 18-mer overlapping peptides (OLPs), 
overlapping by 10 amino acids that spanned the entire HIV-1 proteome. These were 
arranged into 72 pools of between 10 to 12 peptides in each pool such that an individual 
peptide was uniquely represented in two different pools. Each megamatrix peptide pool 
was co-cultured with 100,000 CD8-depleted cells per well in 96-well polyvinylidene 
plates (MAIP S45, Millipore, MA, USA) pre-coated with 100μl MAb1-D1k anti-IFN-γ 
monoclonal antibody (0.5μg/ml) (Mabtech, Stockholm, Sweden) overnight at 4ºC.  
Positive responses from initial megamatrix screening were confirmed using a separate 
ELISPOT assay at the single peptide level. For screening at the single peptide level, a 
total of 100,000 CD8-depleted PBMC per well were plated in 96-well polyvinylidene 
plates (MAIP S45, Millipore, MA, USA), pre-coated with 100μl MAb1-D1k anti-IFN-γ 
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monoclonal antibody (0.5μg/ml) (Mabtech, Stockholm, Sweden) overnight at 4ºC, in the 
presence or absence of specific HIV-1 derived OLPs in a final volume of 200 μl R10 
medium (RPMI 1640 containing 10% heat-inactivated fetal calf serum, 2 mM L-
glutamine, 50 U/ml of penicillin, 50 μg of streptomycin/ml, and 10 mM HEPES). Each 
well contained a single OLP (10 µl) at a final concentration of 2 μg/ml for each individual 
peptide. Cells in medium without antigenic stimuli represented negative controls. The 
addition of phytohemagglutinin antigen (PHA) (Sigma-Aldrich, St Louis, MO, USA), at 
a concentration of 5μg/ml, served as a positive control for both cell viability and 
functionality of the immunoassay. The plates were incubated for 40 hours at 37°C, 5% 
CO2 to elicit maximum cytokine secretion. The ELISPOT plates were then processed as 
previously described (21). An antigen-specific CD4+ T cell response was considered 
positive only if it was at least ≥3 times the mean background and also ≥3 times the 
standard deviation of the SFC (spot forming cells) within the negative controls. The 
breadth of responses was defined as the sum of IFN-γ-positive peptide responses within 
a given individual across the entire HIV proteome or within a specified protein. Positive 
responses to two adjacent overlapping peptides were relatively rare in our cohort (2/30 
responders), but where they occurred, the two overlapping peptides were treated as a 
single epitope to ensure that the breadth of CD4+ T cell responses was not over-estimated.  
 
2.4.3 HLA genotyping 
High-resolution (4-digit allele) class I/II genotyping was carried out using standard 
sequence-based typing protocols (16). In brief, HLA class I genes were amplified by PCR, 
with primers spanning exons 2 and 3, with HLA class II typing based on exon 2. 
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Sequencing results were interpreted using the ASSIGN 3.5 software developed by 
Conexio Genomics (Fremantle, Western Australia, Australia). 
 
2.4.4 HIV-specific CD4+ T cell lines and HLA-DR restriction assay 
 
A modified HLA-DRB1 restriction assay was utilized as previously described (12) to 
define restricting HLA class II alleles. In brief, frozen CD8-depleted PBMC samples from 
subjects with known CD4+ T cell responses were used to generate CD4+ T cell lines. 
CD8-depleted PBMC was stimulated with 10 µg/mL of peptide at a concentration of 2 
million cells on a 24-well plate in R10 medium. The cells were incubated at 37°C and 5% 
CO2. After 2 days, the cells were washed and fresh R10 medium supplemented with 100 
U/mL recombinant interleukin-2 (IL-2) was added. The CD4+ T cell lines were fed twice 
weekly with regular media replenishment. After 14 days, the T cell lines were 
simultaneously assessed for their specificity and HLA-DR restriction using a large panel 
of L cell lines (LCLs), which are mouse fibroblasts, each stably transfected with a single 
recombinant human HLA-DR molecule, as previously described (22). Each LCL was 
pulsed with 10 μg/mL peptide for 90 minutes at 37°C and 5% CO2 and washed five times 
to remove free peptide. Clade C consensus sequence HIV-1 overlapping peptides were 
used in the assay. 10,000 peptide-pulsed LCL were co-cultured in triplicate with 50,000 
of each respective CD4+ T cell line per well on a pre-coated IFN-γ plate. As a negative 
control, each CD4+ T cell line was co-cultured in triplicate with the appropriate LCL in 
the absence of peptide. As a positive control, PHA was added at 2μg/mL. The plates were 
incubated for 18 hours at 37°C and 5% CO2 and processed as per usual ELISPOT protocol 
described above. The AID ELISpot reader (Autoimmun Diagnostika, Germany) was used 
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to determine the number of spot-forming cells (SFC) per 50,000 of the CD4+ T cell line. 
HLA-DR restriction was considered positive if it was at least ≥3 times the mean 
background and also ≥3 times the standard deviation of the negative control wells. 
 
2.4.5 MHC Class II tetramers 
 
HIV p24 clade C Gag41 peptide (YVDRFFKTLRAEQATQDV) was complexed to 
recombinant human DRB1*11:01 or DRB1*13:01.  In addition, HIV p24 clade C Gag37 
peptide (WIILGLNKIVRMYSPVSI) was complexed to recombinant human 
DRB1*13:01 and DRB1*03:01. These tetramers are referred to as the specific HLA 
together with the peptide designation hereafter (e.g. DRB1*11:01-Gag 41). All tetramers 
were PE- and APC-conjugated at a concentration of either 454nM or 432nM. The 
tetramers were produced in the laboratory of Dr Søren Buus under previously described 
conditions (23).    
 
2.4.6 Tetramer and surface staining 
 
Unless stated otherwise, PBMC were incubated with MHC class II tetramers with a final 
staining concentration of 30 nM for one hour at 37°C in media. Post washing with cold 
2% FCS/PBS buffer, antibodies to cell surface molecules were added and incubated at 
4°C for 30 minutes. The following anti-human-conjugated antibodies were used: CD3-
BV785-OKT3 (BioLegend, San Diego, CA, USA, Cat No. 317330), CD4-AF700-RPA-
T4 (BD, San Jose, CA, USA, Cat No. 557922), CD8-BV605-SK1 (BD, Cat No. 564116). 
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PBMC’s were also stained with live/dead fixable aqua cell viability dye (Invitrogen, 
L34957). Stained cells were washed with 2% FCS/PBS buffer and fixed with fixation 
medium A (Invitrogen, GAS001S-100). Data was acquired on a LSRFortessa™ (Serial # 
H647794E6049, BD). Flow data were analyzed using FlowJo software (Treestar FlowJo, 
version 10.1, Ashland, OR, USA). 
 
2.4.7 Intracellular cytokine staining 
 
Briefly, PBMC were incubated overnight with a clade C consensus Gag peptide pool or 
Gag41 as specific antigen/stimulus, and Staphylococcal enterotoxin B (SEB) (Sigma) as 
a positive control, in the presence of Golgi stop protein transport inhibitor (BD 
Biosciences) and Golgi plug protein transport inhibitor (BD Biosciences), according to 
manufacturer’s instructions. Anti-CD107a-PECy5-H4A3 (BD, 555802) was also added 
at the beginning of the stimulation period. Post the stimulation, intracellular cytokine 
staining was performed according to the BD Biosciences ICS protocol. Unstimulated 
cells were used as a control. Cells were stained with live/dead fixable aqua dead cell 
viability dye (Invitrogen, L34957) and fluorescent antibodies against CD3-BV711-OKT3 
(BioLegend, 317328), CD4-BV650-SK3 (BD, 563875), CD8-AF700-RPA-T8 (BD, 
557945). Cells were permeabilized and fixed with BD intracellular staining reagents 
according to the manufacturer’s instructions (BD Bioscience) and stained with cytokine-
specific antibodies against IFN-γ – PECy7- B27 (BD, 557643), IL-21 – PE – 3A3-N2.1 
(BD, 560463) and IL-2– FITC– 5344.111 (BD, 340448). Cells were acquired on an 
LSRFortessa™ (Serial # H647794E6049, BD). Flow data was analyzed using FlowJo 
software (Treestar FlowJo version 10.1). 
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2.4.8 Ex vivo expansion of HIV-specific CD4 T cells 
 
MHC class II tetramer staining was performed prior to culture. Cells were then cultured 
at 37°C, 5% CO2 for 14 days in the presence of HIV p24 clade C Gag 37 and 41 OLPs, 
as described above for HIV-specific CD4+ T cell lines. On day 14, cells were washed 
three times with fresh R10 media and rested at 37°C, 5% CO2 overnight in fresh R10 
media. The following day, MHC class II tetramer staining was performed to determine 
the levels of expansion. The cells were then stimulated for 6 hours with the same peptides 
used for expansion, and cytolytic activity of the expanded cells was assessed by ICS 
staining forgranzymeA-AF488-CB9 (BioLegend, 507212), granzyme B-AF700-GB11 
(BD, 560213) and CD107a-PECy5-H4A3 (BD, 555802).  
 
2.4.9 Statistical analysis 
Statistical analysis and graphical presentation were performed using GraphPad Prism 
version 5.0 software (GraphPad Software Inc., La Jolla, CA, USA). Spearman’s Rank 
correlation was used to assess the relationship between immune responses and viral load. 
Statistical analysis of significance was calculated using Kruskal Wallis test with Dunn’s 
post hoc analyses for multiple comparisons. Significance of the non-random associations 
(contingency) between controllers and progressors were computed using Fisher's exact 
test, additionally Mann-Whitney U test was utilized to compare differences between the 






To better understand the role of HIV-specific CD4+ T cell responses in HIV viral control 
and disease progression, we comprehensively investigated the specificity and functional 
properties of these responses in the setting of chronic clade C HIV-1 infection using IFN-
γ ELISPOT and multi-parameter flow cytometry with MHC class II tetramers. Modified 
IFN-γ ELISPOT assays were used to identify immunodominant HIV-specific CD4+ T cell 
epitopes and restricting alleles in our chronic infection cohort to inform the production of 
appropriate MHC class II tetramers. MHC class II tetramers were then utilized to detect 
low frequency populations of antigen-specific CD4+ T cells (that may be missed in 
conventional peptide-stimulus based assays). This approach enabled the direct ex vivo 
characterization of antigen-specific HIV-specific CD4+ T cell responses targeting 
immunodominant Gag epitopes. 
 
2.5.1 Immunodominance hierarchy of CD4+ T cell responses in chronic clade C 
infection. 
Here, we evaluated a cohort of 72 clade C untreated, chronically HIV-infected 
individuals. HIV-specific CD4+ T cell responses were initially screened against a panel 
of 410 pooled peptides spanning the entire HIV-1 clade C consensus sequence using the 
IFN-γ ELISPOT megamatrix assay. Results from the initial megamatrix screening were 
validated using confirmatory IFN-γ ELISPOT assays at the single peptide level. Our data 
demonstrate that HIV-specific CD4+  T cell responses in chronic clade C infection 
dominantly target the Gag protein (Figure 2.1A). The most commonly targeted region in 
Gag was the p24 sub-protein (20/63 peptides), while the p17 and p15 regions of Gag were 
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sub-dominantly targeted by CD4+ T cells (12/63 peptides each). The p24 region of Gag 
has also been shown to be immunodominant for HIV-specific CD8+ T cell responses and 
these responses have previously been associated with viral control (24). However, no 
correlation was observed between the breadth of Gag-specific CD4+ T cell responses 
(Spearman r= -0.17, p=0.42) , as well as the magnitude of these responses (Spearman r= 
0.22, p=0.30), as measured by ELISPOT, and contemporaneous viral load. At the epitope 
level, our data showed that Gag41 within the p24 sub-unit is the most immunodominant 
peptide, with over 40% of subjects in our cohort showing a detectable response to this 
peptide (Table 2.2). A previous study found Gag6 in p17 to be the most dominant epitope 
(17). The difference may be due to differing proportions of controllers and progressors 
between the two studies. 
 
The second most commonly targeted epitope was Gag40 (23%). Interestingly, only two 
responders targeted both the adjacent peptides, indicating the presence of distinct epitopes 
rather than targeting of the shared overlap represented in each peptide. Gag6, 25 and 37 
were targeted independently by 20% of the 30 responders (Table 2.2). Additional 
immunodominant epitopes were located within the Nef region of the proteome (7/63 
peptides). The results highlight a large number of detectable HIV-specific CD4+ T cell 
responses across the HIV proteome, dominantly targeting Gag and Nef, consistent with 
previous studies (17). We observed that Gag-specific CD4+ T cell responses are 
immunodominant and are directed at multiple distinct epitopes, with very few detectable 
CD4+ T cell responses to Env or accessory proteins. This is in contrast to studies in 
chronic clade B infection, which have detected CD4+ T cell responses targeting multiple 
epitopes within Env gp120 and rarely target OLP 25 in Gag (21), suggesting that the 
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immunodominance hierarchy of HIV-specific CD4+ T cell targeting may be influenced 
by the infecting clade (25). Moreover, our study has identified 22 peptides that have not 
been described as immunodominant epitopes in previous clade C studies. 
 
As the cohort was stratified into controllers and progressors, we next evaluated whether 
HIV-specific CD4+ T cell responses within these two groups may be directed at different 
epitopes. However, there was no significant difference between the two groups (p=0.65) 
(Figure 2.1B). A few epitopes were exclusively targeted by each group, at low frequencies 
of 3%. There were particular epitopes that, albeit targeted by both groups, were more 
targeted by progressors, such as Gag25, which was targeted by only 3% of controllers 
and 13% progressors (Fischer’s exact test p=0.01). Notably, the highly immunodominant 
Gag41 epitope was targeted by both controllers and progressors (at 23% and 17% 
responders, respectively), thus providing sufficient coverage of both groups for in-depth 
quantitative and qualitative evaluation of the Gag-41-specific CD4+ T cell responses by 
MHC class II tetramers and the relationship of these responses to viral load. 
 
 




aPatient demographics were as follows: Sex (76.3% female, n=61 and 23.8% male, n=19) and 
Race (97.5% African, 1.2% each Asian and Caucasian). All study participants included in 
tetramer and intracellular cytokine staining studies maintained viral control for a minimum of one 
year including at time point of analysis in the case of controllers and had comparable CD4 cell 
counts (p = 0.87). Individuals utilized for the initial screening and HLA restriction assays were 





Figure 2.1 (A) Percentage frequency targeting of HIV-specific CD4+ T cell responses to 
overlapping peptides across the HIV-1 proteome. HIV-specific CD4+ T cell responses 
were screened against a panel of 410 overlapping peptides (OLPs) spanning the entire 
HIV proteome. Labels on X-axis indicate the start of the relevant HIV protein or sub-
protein. The frequencies of responders (30/72 individuals screened) with epitope-specific 
CD4+ T cell responses are shown. (B) Percentages of epitope-specific CD4+ T cell 
responses targeting respective OLPs across the Gag and Nef proteins between controllers 
(blue bars; n=13) and progressors (red bars; n=17) from a chronically infected cohort. No 
significant differences were observed between the two groups (p=0.65; based on non-
parametric two-tailed t-test). Further analysis for each individual response indicated a 
significant predominant targeting of OLP-25 by progressors compared to controllers 











Table 2.2 Immunodominant peptides targeted by study participantsa 
 
a Immunodominance hierarchy of frequently targeted HIV-specific CD4+ T cell responses in 
chronic clade C HIV infection cohort. Percentages are calculated according to those individuals 





2.5.2 HLA-DRB1*13:01 and DRB1*11:01 are the most frequent alleles among CD4+ 
T cell responders. 
Having identified immunodominant epitopes targeted in chronic clade C infection, we 
next performed class II HLA-typing as described in the methods to determine HLA-class 
II allele frequencies among the subjects with detectable responses by IFN-γ ELISPOT 
assay (n=30) (Figure 2.2A). Our data suggest that individuals with the strongest HIV-
specific CD4+ T cell responses possessed the class II HLA-DRB1*13:01 allele (n=12, 
21% of responders). The next most common alleles were DRB1*11:01 and DRB1*03:02, 
expressed by 14% and 9% of responders, respectively.  Interestingly, the most common 
DRB1 alleles among the responders in our study were also the most frequent in the larger 
chronic clade C cohort (n=439) whereby DRB1*03:02 was the most common allele 
observed (n=146, 33%) followed by DRB1*11:01 (n=111, 25%) and DRB1*13:01 
(n=102, 23%) (16) . It is important to note that DRB1*13 alleles has been reported to 
confer a protective effect (13), with DRB1*13:03 in particular having been shown to 
mediate protection independent of ethnicity, sex, and viral clade (16). 
 
2.5.3 HLA-DRB1 allele restriction characteristics of HIV-specific CD4+ T cell 
responses in clade C infection. 
Having defined the frequencies of these class II alleles in this chronic infection cohort, 
we next identified DRB1 restricting alleles using the HLA-restriction assay previously 
described by Ranasinghe et al. (12). We observed high levels of peptide promiscuity, 
which is known to be a distinctive feature of antigen-specific CD4+ T cell recognition 
(22), with the presentation of a single peptide on numerous HLA class II variants. Gag41 
in the Gag p24 region, previously identified as the most frequently targeted epitope by 
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HIV- specific CD4+ T cells in clade B (17, 21), and shown in this cohort to also be the 
most frequently targeted, exhibited the highest levels of promiscuity, restricted by 7 
different HLA-DRB1 variants (Figure 2.2B). The promiscuity in peptide-binding is likely 
mediated by the open conformation of HLA class II, allowing for long peptides 
recognized by CD4+ T cells to extend beyond the HLA binding groove (12). Despite the 
high degree of HLA-DRB1 binding promiscuity, marked differences were observed in 
the number of peptides that were restricted by each DRB1 variant. Variants such as 
DRB1*14:01 and DRB1*04:01 had no detectable contribution to overall peptide 
restrictions as compared to DRB1*13:01 and DRB1*11:01 which had 9 and 4 HIV-
specific peptides restricted, respectively. 
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Figure 2.2 HLA class II restriction characteristics of HIV-specific CD4+ T cell responses 
in a chronic clade C infection cohort. (A) Percentage frequency of various HLA-DRB1 
allele variants in CD4+ T cell responders (n=30). The number of responders possessing 
each allele is indicated in parenthesis above each bar. (B) HLA-DRB1 allele restriction 
characteristics of HIV-specific CD4+ T cell responses in clade C infection (promiscuous 
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epitopes). The restricting HLA alleles for each overlapping peptide are indicated above 
each bar. Alleles that are highlighted in red were used to generate MHC class II tetramers. 
 
2.5.4 Use of HLA class II tetramers for sensitive detection of HIV-specific CD4+ T 
cells. 
Having identified immunodominant CD4+ T cell epitopes and the most common 
restricting HLA DRB1 allele variants in a large number of clade C responders (30/72 
individuals tested), the information was used to successfully generate and validate the 
following tetramers; DRB1*03:01 (Gag37), DRB1*11:01 (Gag41), and DRB1*13:01 
(Gag37 and Gag41), each conjugated to both PE and APC (Table 2.3). The newly 
synthesized tetramers were then used to evaluate the role of HIV-specific CD4+ T cell 
responses in the pathogenesis of clade C HIV-1 infection. To our knowledge, these 
particular MHC class II tetramers have not been synthesized before in the setting of clade 
C infection. Furthermore, our study is the first to generate and utilize the DRB1*11:01 
tetramer to Gag41 to study CD4+ T cell responses. 
 
Given the low frequency of HIV-specific CD4+ T cell responses (26), a dual PE and APC 
tetramer staining strategy gating on double staining cells was used to increase our ability 
to detect genuine tetramer+ cells and minimize non-specific background staining (Figure 
2.3A). Class II tetramer staining was also assessed on CD8+ T cells for each sample to 
ensure that there was minimal non-specific tetramer binding (Figure 2.3A). The 
specificity was confirmed by staining 3 HIV negative samples, none of which stained 
positive (representative data shown in Figure 2.3B). Low frequency class II DRB1*03:01, 
*11:01 and *13:01 tetramer binding CD4+ T cells were readily detectable in 11 controllers 
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expressing requisite DRB1 alleles at a median frequency of 0.31% (IQR 0.045% to 
0.41%) of the total CD4+ T cells. Notably, the median frequency of class II tetramer 
binding cells in 10 chronic progressors expressing the requisite DRB1 was 0.036% (IQR 
0.015% to 0.27%, p=0.0001) which is 10 fold lower than in controllers (Figure 2.3C). 
Analysis of the DRB1*11-Gag41 tetramer binding responses also showed higher 
frequency in controllers than progressors (p=0.0005, Figure 2.3D). The controllers and 
progressors were matched for expression of DRB1*11, with an equal number of each 
expressing this allele. These data suggest that HIV-specific CD4+ T cell responses 
targeting immunodominant Gag41 in the context of DRB1*11 expression are associated 
with maintenance of low viremia during chronic clade C HIV infection.  
 
Table 2.3 MHC Class II tetramersa used for analysis of tetramer+ CD4+ T cells 
 
aMHC class II tetramers were produced according to allele variants associated with most 





Figure 2.3 Frequency of tetramer positive CD4+ T cells in controller and progressor 
chronically infected individuals and HIV negative subjects. (A) Representative flow plots 
indicating a dual PE and APC tetramer staining strategy gating on double stained cells, 
which was used to increase the ability to detect genuine tetramer+ cells and minimize 
non-specific background staining on CD8+ T cells, from an HIV infected individual and 
(B) from a HIV negative individual. (C) Differences in the percentage of CD4+ tetramer+ 
T cells between controllers (blue) and progressors (red) for all class II DRB1*03:01, 
*11:01 and *13:01 tetramers utilized (p= 0.0001) and (D) for only DRB1*11:01 tetramer 
(p= 0.0005). 
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2.5.5 Dominance of mono-specific HIV-specific CD4+ T cell responses in controllers 
and progressors. 
Given that tetramers can bind antigen-specific cells irrespective of function, we next 
examined the range of CD4+ T cell functionalities that constitute tetramer+ responses. 
PBMCs were stimulated withHIV clade C Gag pool or Gag 41 or 37 OLPs. Multicolour 
flow cytometry was used to detect and enumerate key effector CD4+ T cell functions in 
individuals with tetramer+ responses. We measured markers that define key CD4+ T cell 
functional subsets. Our analysis included the degranulation marker CD107a, used to 
enumerate cytolytic CD4+ T cells (7), IFN-γ and IL-2 used to identify Th-1 helper cells 
(27), and IL-21 was included to identify cells that augment B cell and CD8+ T cell effector 
functions (9, 28). To investigate if any of the measured functions impact virus 
suppression, we compared the expression level of each marker in controllers and 
progressors. HIV controllers’ responses exhibited higher mean/median expression of 
each of the four functions compared to progressors in response to stimulation with a mix 
of Gag peptides (Figure 2.4A,B), or in response to the immunodominant Gag41 (Figure 
2.4C), or in response to SEB (Figure 2.4D), yet only SEB reached statistical significance 
after correction for multiple comparisons. Previous studies show that the ability to 
simultaneously elaborate multiple functions is associated with protective immunity 
against several viral infections (Reviewed by Harari et al., (29)), moreover, 
multifunctional CD4+ T cell responses were associated with protection in the RV144 trial 
(30-32). Therefore, we next examined if certain combinations of functions were 
associated with slow HIV disease progression. Combinatorial polyfunctionality analysis 
showed a preponderance of mono-specific responses for both controllers and progressors 
(Figure 2.4E, F). The high frequency of mono-functional cells highlights the limitation 
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of assays which rely on a single function as a surrogate for the entire HIV-specific CD4+ 
T cell response. 
 
 
Figure 2.4 HIV-specific CD4+ T cell polyfunctional responses (A) Graphical 
representation of intracellular cytokine staining of controller and progressor individuals 
based on CD107a stimulation. Expression of CD107a, IFNγ, IL-2 and IL-21 were 
 61 
measured in 14 chronically infected subjects, divided into controllers (blue) and 
progressors (red) in responses to Gag pool stimulation (B), to Gag41 stimulation (C) and 
to SEB stimulation (D). (E, F) The bars depict the frequency of CD4+ T cells expressing 
a combination of functions indicated below the x-axis. 
 
2.5.6 Gag-specific tetramer+ CD4+ T cell responses inversely correlated with HIV 
viral load. 
Given the observed link between CD4+ T cells responses and maintenance of low viremia, 
we next interrogated whether maintenance of Gag-specific (tetramer+) CD4+ T cell 
responses during chronic HIV infection influence disease progression. The frequency of 
Gag-specific CD4+ T cells measured by four MHC class II tetramers negatively correlated 
with contemporaneous viral load (Spearman r=-0.5, p=0.005) when both controllers and 
progressors were analyzed together (Figure 2.5A). However, separate analysis of 
controllers (Spearman r= 0.3, p=0.3) and progressors (Spearman r= -0.01, p=0.9) 
responses did not reach statistical significance, which may be due to the small sample 
size. Furthermore, a negative correlation was also observed between the frequency of 
tetramer+ CD4+ T cells targeting DRB1*11-Gag41 and contemporaneous viral load 
(Spearman r=-0.5, p=0.02) (Figure 2.5B). Interestingly IFN-γ secretion measured by ICS 
exhibited a similar negative correlation with viral load (Spearman r=-0.7, p=0.003) 
(Figure 2.5C). However, IL-2, IL-21 and CD107a did not correlate with contemporaneous 
viral load (Data not shown).  This observation prompted us to examine the relationship 
between tetramer+ CD4+ T cells and cytokine+ cells following stimulation with Gag 
peptides. Interestingly, only IFN-γ secreting cells correlated with tetramer+ cells 
(Spearman r=0.7, p=0.001) (Figure 2.5D). There was no correlation between IL-2 or IL-
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21 and frequency of tetramer+ responses (Figure 2.5 E, F) and only borderline 
significance of an association with the CD107a degranulation marker (p=0.04, Figure 
2.5G). The plausible explanation for the lack of positive correlation between tetramer+ 
cells and these cytokine+ cells may be because some IL-2 and IL-21 secreting cells 
recognized different epitopes within Gag or alternatively, were restricted by other class 
II alleles.  
 
Overall, these data highlight the heterogeneity of the effector functions of HIV-specific 
CD4+ T cells and illustrates the advantage of using tetramers to identify antigen-specific 
cells without relying on function. Furthermore, these data suggest that immunodominant 
Gag-specific CD4+ T cell responses are linked with better control of HIV, indicating that 






Figure 2.5 Gag-specific tetramer+ CD4+ T cell responses correlates with markers of HIV 
disease progression. (A) The frequency of HIV-specific CD4+ T cells measured by four 
class II tetramers negatively correlated with contemporaneous viral load (Spearman –r 
=0.7, p=0.005). (B) A negative correlation was also observed between the most dominant 
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Gag41 response (DRB1*11:01) and contemporaneous viral load (C) IFN-γ secretion 
measured by ICS exhibited a similar negative correlation with viral load (Spearman r=-
0.7, p=0.003). In addition, the relationship between tetramer+ CD4+ T cells and cytokine+ 
cells following stimulation with HIV peptides was analysed (D-G). 
 
2.5.7  Ex vivo expanded HIV-specific CD4+ T cells display increased cytolytic activity 
in controllers. 
The low frequency HIV-specific CD4+ T cells detected by class II tetramers may be 
mostly low frequency memory responses, which have low potential to secrete cytokines 
ex vivo. Moreover, several studies in HIV-specific CD8+ T cell responses have 
demonstrated that ex vivo expansion is needed to accurately measure the cytolytic 
potential of memory responses (33, 34). We reasoned that this might also be true for HIV-
specific CD4+ T cell responses.  Thus, we next performed stimulated expansion of low 
frequency HIV-specific CD4+ T cells that were detected by tetramers and evaluated the 
cytolytic potential of these expanded cells. Cultured stimulation of HIV-specific CD4+ T 
cells from controllers resulted in significant expansion of tetramer+ populations compared 
to baseline levels (p=0.03, Figure 2.6A and B), whereas class II tetramer+ populations 
from progressors expanded poorly (p=0.2) (Figure 2.6C and D). Assessment of the 
cytolytic activity of ex vivo expanded HIV-specific CD4+ T cells by intracellular cytokine 
staining (Figure 2.6E) showed that controllers had significantly higher proportion of HIV-
specific cells expressing granzyme A (p=0.03) and granzyme B (p=0.01) compared to 
progressors (Figure 2.6F). No significant differences were observed for CD107a between 
the groups. Taken together these data suggest that HIV-specific CD4+ T cells from 
controllers have higher proliferative and cytolytic functions when compared to 
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progressors, suggesting their potential contribution to direct antiviral activity during 




Figure 2.6 Frequency of tetramer positive CD4+ T cells in controller and progressor 
chronically infected individuals following cell expansion. (A) Representative flow plots 
indicating a dual PE and APC tetramer staining strategy gating on double stained cells at 
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baseline and 2 weeks following expansion of peptide specific T cell lines, from an HIV 
controller and (C) from an HIV progressor  (B) Differences in the percentage of CD4+ 
tetramer+ T cells in 3 controllers, indicating responses  at baseline and 2 weeks after 
expansion in culture (red) for all class II DRB1*03:01, *11:01 and *13:01 tetramers 
utilized (p= 0.02) and (D) for 3 progressors, using the same principle. (E) Representative 
flow plots indicating functional responses by IFNγ – specific CD4+ T cells to Granzyme 
A, Granzyme B and CD107a following 2 weeks of expansion and (F)  Comparison of 
IFNγ – specific CD4+ T cells between controllers and progressors to Granzyme A (p= 
0.03), B (p= 0.01) and CD107a (p=0.9). 
2.6 Discussion 
 
Together these data demonstrate an association between the frequency of HIV-specific 
CD4+ T cell responses targeting distinct immunodominant epitopes in Gag and immune 
control of clade C HIV viremia.  In particular, we show that CD4+ T cells targeting Gag41 
in the context of HLA-DRB1*11 are associated with immune control of HIV (in HLA-
matched individuals). To our knowledge, this is the first study to demonstrate that CD4+ 
T cells directed against a single peptide-HLA class II specificity are associated with low 
HIV viremia. Indeed, although CD8+ T cell targeting of HLA class I-peptide complexes 
such as B*27-KK10 are well-known to associate with spontaneous control of HIV 
infection (35, 36), previous studies assessing the contribution of HIV-specific CD4+ T 
cells to HIV immune control have focused either on the expression of distinct HLA-
DRB1 alleles (12-14, 16), or identified particular CD4+ T cell epitopes such as Gag41 
targeted at different stages of disease (17, 21, 25, 37).  The finding that there is an 
association between the frequency of HIV-specific CD4+ T cells targeting the DRB1*11-
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Gag41 complex and low HIV viremia (in our assessment of 20 HIV-positive HLA-
matched individuals) is consistent with our hypothesis that the maintenance of robust 
HIV-specific CD4+ T cell responses to the Gag p24 region may contribute to immune 
control of chronic HIV replication, rather than to fuel disease progression through 
infection of activated HIV-specific CD4+ targets.  
 
It is important to note that although the frequency of HIV-specific CD4+ T cells measured 
by four MHC class II tetramers negatively correlated with contemporaneous viral load 
when controllers and progressor were analyzed together, the correlation did not reach 
statistical significance when each group was analyzed separately. This may due to smaller 
sample size. Nevertheless, the fact that controllers maintained higher frequencies of class 
II tetramer+ CD4 T cells compared to progressors, suggests an association between higher 
frequencies of virus-specific CD4+ T cells responses and maintenance of lower viral 
loads. 
 
Although our analysis of peptide-stimulated HIV-specific CD4+ T cells found that they 
predominantly secreted IFN-γ directly ex vivo, we speculate that in vivo these epitope-
specific CD4+ T cells may provide superior helper activity to HIV-specific CD8+ T cells 
that enhance suppression of HIV replication through a cocktail of cytokine signals, or 
they may directly kill HIV-infected CD4+ T cell and macrophage targets. Indeed, the 
finding that our ex vivo expanded CD4+ T cell lines expressed granzyme A and B, were 
significantly enhanced in HIV controllers, support the hypothesis that CD4+ T cells 
targeting immunodominant Gag peptides may exhibit functions that contribute to immune 
control of HIV (7, 38). However, since it is not possible to determine cause versus 
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consequence in our cross-sectional analysis, it remains unclear whether weak HIV-
specific T cell responses are a result of ongoing viral replication, or alternatively whether 
the superior frequency and function of these responses either contributes to effective 
immune control of the virus, or that some T cell specificities may simply be better 
preserved in individuals with low viremia and low immune activation. 
 
The improved elucidation of HIV-specific CD4+ T cell responses and enhanced 
understanding of how such CD4+ T cells may promote the generation of protective CD8+ 
T cell and B cell responses or mediate a direct antiviral role is highly relevant for future 
HIV vaccine design. Currently, developing assays that can fully quantify all the relevant 
epitope specific responses remains a major challenge in natural infection and vaccine 
studies because of the tremendous complexity of CD4+ T cell biology. This study 
employed MHC class II tetrameric complexes to enumerate and characterize Gag p24-
specific CD4+ T cell populations ex vivo in HIV infected individuals bearing HLA 
DRB1*11:01, DRB1*13:01 and DRB1*03:01 alleles. Overall, our study shows that MHC 
class II tetramers are very sensitive methods for detecting very low cell frequencies of 
HIV-specific CD4+T cells directly ex vivo. Our approach provides an alternative method 
of identifying antigen-specific CD4+ T cell without relying on function and removes the 
bias associated with in vitro stimulation required for functional assays and the limitation 
associated with only detecting subsets of cells capable of secreting cytokines. Yet, a 
notable limitation of our study is the lack of availability of a wide range of class II 
tetramers complexed with other MHC class II DRB1 alleles, or the less-well characterized 
DP and DQ alleles. Notwithstanding this limitation, the ELISPOT screening data show 
that we were able measure most of the immunodominant responses, which are restricted 
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by DRB1 alleles pertinent to this African population for which we successfully generated 
a subset of the relevant class II tetramers. Taken together, these data demonstrate that 
HIV-specific CD4+ T cell responses restricted to DRB1*11-Gag41 are associated with 
immune control of HIV-1 infection and highlight the advantages of class II tetramer 
technology in evaluating HIV-specific CD4+ T cells responses in future natural infection 
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 Chapter 3 Overview 
 
Our results in chapter 2 demonstrated that usage of MHC class II tetramers is very 
sensitive for directly detecting ex vivo HIV-specific CD4+ T cells present at very low 
frequencies. Our approach provides an alternative method of identifying antigen-specific 
CD4+ T cells without relying on function and removes the bias associated with in vitro 
stimulation of cells for functional assays and the limitation of only detecting cell subsets 
capable of secreting cytokines. 
 
Having validated these tetramers in peripheral blood, in our clade C chronic infection 
cohort, we next wanted to further our investigations and utilize these MHC class II 
tetramers in interrogating low frequency HIV-specific regulatory T cell populations in 
lymph nodes and peripheral blood. Among the CD4+ T cell populations, regulatory T 
cells (TREGs), have been shown to be essential for the maintenance of self-tolerance and 
immune homeostasis. More recently, evidence suggests that B-cell follicles and germinal 
centers within secondary lymphoid tissue contain a novel subset of TREGs, termed 
follicular regulatory T cells (TFR). Much of the work conducted on CD4+ T cell subsets 
within lymph nodes focuses on T follicular helper (TFH) cells, with limited knowledge 
available on the cells that regulate the functional capacity of these cells.  
 
In chapter 3 of this thesis, we focus on phenotypically, transcriptionally and functionally 
characterizing TFR as a distinct subset from TFH in peripheral blood and lymphoid tissue. 
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Regulatory T cells (TREGs) play a fundamental role in the maintenance of tolerance as 
well as in the control of immune activation, particularly during chronic infections. The 
role of TREGs during HIV infection is still poorly understood, with both detrimental and 
beneficial roles having been proposed. More recently TREGs have been shown to be 
precursor cells for T follicular regulatory (TFR) cells, a subset of regulatory cells shown 
to enter the B cell follicles and modulate T follicular helper (TFH) cells and B cells to 
control the germinal center (GC) reaction. Being a relatively newly identified subset, 
much remains to be discovered regarding TFR biology, phenotype and function in HIV-1 
infection. Thus, we set out to elucidate the phenotypic and transcriptional markers that 
better define TFR and distinguish them from regulatory (TREG) and T follicular helper 
cells (TFH cells), using lymph nodes (LN) and peripheral blood (PBMC) samples.  
 
We studied 31 individuals, grouped into HIV uninfected and HIV infected early ART 
initiators and untreated individuals, from a clade C HIV infection cohort in Durban, South 
Africa. TREG (CD4+FOXP3+), TFH (CD4+CXCR5+PD-1) and TFR 
(CD4+CXCR5+PD-1+CD25+CD127-) phenotypes were defined using flow cytometry. 
Transcriptional signatures and unique transcriptional markers of TFH and TFR were 
assessed using single cell RNA-sequencing Seq-Well assays and their antigen-specificity 
were determined using MHC class II tetramers.  
 
Frequencies of total TREG, TFH and TFR cells were comparable in LNs of HIV 
uninfected individuals, with increased TFH compared to TFR observed in PBMCs of the 
same individuals (p=0,002). TFR shared phenotypic and transcriptional markers with 
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both TREGs and TFH as determined by both flow cytometry and Seq-Well assays. 
However, these cells are a distinct subset of CD4+ T cells as seen by unique identifying 
transcriptional signatures determined by Seq-Well. Antigen-specific TFR were identified 
in LN of HIV-infected individuals, with higher frequencies observed during untreated 
HIV infection. Lastly, regulatory subsets, TREGs and TFR did not show any changes in 
frequencies upon HIV infection or treatment initiation.  
 
Our results show TFR are indeed a distinct CD4+ regulatory T cell subset within lymph 
nodes and peripheral blood. Better understanding of regulatory subsets in terms of 
phenotypic heterogeneity and antigen-specificity, particularly within LN, will enhance 
the ability to identify and track these cells, and will open up opportunities for 
manipulation for immunotherapies advantageous to the HIV-infected host. 
3.2 Introduction 
 
CD4+ T cell responses are essential in the development of effective cellular and humoral 
immune responses against viral infections. Amongst the CD4+ T cell populations, 
regulatory T cells (TREGs) have been shown to play a crucial role in the maintenance of 
tolerance as well in the control of immune activation, more so during chronic infections 
(1-3). TREGs have been associated with various roles during HIV infection and their 
function may be affected by the initiation of/or ongoing therapy (4-6). Within the 
regulatory networks, T follicular regulatory cells (TFR) have recently been described as 
a novel subset of TREGs which has an overlapping transcriptional pattern with T 
follicular helper cells (TFH) (7-9). A recent study showed that CXCR5 expressing TFR 
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originate from TREG precursors and regulate GC responses through interactions with 
TFH (10). Furthermore, studies in SIV have further described the importance of the TFR: 
TFH ratio in regulating autoreactive antibody production and a decreased ratio could 
possibly lead to unchecked expansion of TFH and GC B cells (11, 12).  
 
Antiretroviral therapy (ART) has been the most successful intervention for improving life 
expectancy of HIV-1 infected individuals, allowing for reconstitution of immunity and 
improved adaptive immunity amongst numerous other benefits (13, 14). ART has been 
shown to have a significant influence on TREG cell numbers in HIV-infected subjects, 
decreasing or even normalizing their frequencies to comparable levels with healthy 
controls (15, 16). With other studies reporting that decreased TREG cell numbers were 
found in blood and lymphoid tissues of treated compared to untreated HIV-1 infected 
subjects (1, 17).  
 
The role of TREGs in HIV-1 immune pathogenesis has been widely studied in peripheral 
blood, but much less is known about the role of these regulatory subsets in secondary 
lymphoid organs, where they more likely influence B cells and CD8+ T cell functions 
(18). Understanding the mechanisms by which regulatory CD4+ T cells, particularly 
TFR, exert their influence in lymphoid tissues is an important research area with broad 
implications for the development of therapeutic strategies for many diseases including 
immune mediated diseases, such as HIV-1. Therefore, in-depth understanding of how this 
cell subset modulates induction of adaptive immune responses during HIV infection is 
warranted. 
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To assess heterogeneity and antigen-specificity of regulatory cells within lymph nodes 
(LN) and peripheral blood (PBMC), we recruited 31 individuals (8 HIV negative and 16 
HIV-infected early treated and 7 HIV-infected chronic untreated). Excisional LN and 
paired PBMC were obtained. Flow cytometry, single cell RNA-sequencing (Seq-Well) 
and MHC class II tetramers were used to define the phenotype, transcriptional signature, 
and antigen-specificity of TREG, TFH and TFR cells.  
 
Based on a combination of flow cytometric and transcriptional analyses, TFR cells were 
identified as a distinct subset from TREG and TFH cells. Antigen-specific CD4+ T cells 
were detected, with higher frequencies in LNs compared to PBMC. Furthermore, 
comprehensive analysis of these CD4+ T cells showed TREG, TFH and TFR cells were 
low frequency populations in LN/PBMC. Additionally, analysis of the impact of HIV 
infection and treatment initiation showed no significant changes in frequencies in 
regulatory subsets within LNs or PBMCs. Taken together, these results document three 
distinct CD4+ T cell subsets in human LNs and peripheral blood. Furthermore, these data 
set a foundation for future detailed characterization on the role of TFR in HIV-1 infection, 
where these cells could be used as a therapeutic target to enhance anti-viral humoral 
immunity and vaccine efficacy.  
3.3 Materials and Methods 
3.3.1 Cohort characteristics 
 
A total of 31 participants were used from the HIV Pathogenesis Programme (HPP) lymph 
node study cohort. Informed consent was obtained from all study participants prior to 
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enrolment in the study. Excisional lymph nodes (LN) and paired blood samples were 
obtained from study participants recruited in an on-going protocol approved to recruit 
HIV uninfected and HIV-infected individuals from study sites based in the Umlazi 
Township, Durban, South Africa. In this study, we used 8 HIV negative and 16 early 
treated donors recruited from the FRESH cohort (14)  and 7 chronic untreated participants 
recruited from the HPP Acute infection cohort (19). Inguinal, axillary or cervical LN were 
excised and paired peripheral blood samples were collected from study participants. 
Measurements of CD4+ T cell counts, and viral loads were performed by Global Clinical 
and Viral laboratories (Durban, South Africa). The Biomedical Research Ethics (BREC) 
of the University of KwaZulu-Natal and the institutional review board (IRB) of 
Massachusetts General Hospital approved this study. 
 
3.3.2 Lymph node and peripheral blood sample processing 
Excised LN were sliced into two pieces; approximately 1/3 of the LN was fixed in 10% 
formal-saline (Sigma-Aldrich, St Louis, Missouri, USA) for downstream microscopy 
studies, with the remaining 2/3 mechanically processed to release LN mononuclear cells 
(LMCs) as described by Schacker et al., (20). In brief, the macerated LN was passed 
through a 70uM cell strainer (BD, 352350) into a collection tube containing R10 media. 
Cells were pelleted and collected by centrifugation [1800 RPM, 6 minutes (min), room 
temperature (RT)]. Peripheral blood mononuclear cells (PBMCs) were isolated from 
patient blood samples by density-gradient centrifugation using Histopaque-1077 (Sigma-
Aldrich). LMCs and PBMCs were cryopreserved in liquid nitrogen.  
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3.3.3 Flow cytometric analysis 
Freshly isolated and frozen LMCs and PBMCs were phenotypically and functionally 
characterized using multi-parameter flow cytometry. Standardized protocols using the 
transcription factor diluent buffer set (BD Biosciences, San Jose, CA, 562574) were 
utilized. In brief, for surface staining, cells were incubated for 20 min at RT in the dark 
in staining buffer [2% fetal calf serum (FCS) in phosphate buffered saline (PBS) buffer] 
containing the following antibodies: CD3-AF700-UCHT1 (BD Biosciences, 557943), 
CD4-BV650-SK3 (BD Biosciences, 563875), CD8-PE- RPA-T8 (BD Biosciences, 
555367), CD25- PE-Cy5 -M-A251 (BD Biosciences, 555433), CD127-BV785-A019D5 
(BioLegend, San Diego, CA, USA, 351329), CXCR5-AF488-RF8B2 (BD Biosciences, 
558112), PD-1 – BV421-EH12.2H7 (BioLegend, 329920), CXCR3-BV605-G025H7 
(BioLegend, 353728), ICOS-AF647-C398.4A (BioLegend, 313516) and CCR7- PerCP-
Cy5.5 – T68 (BioLegend, 335605). Cells were also stained with live/dead fixable aqua 
cell viability dye (Invitrogen, L34957). After the incubation period, cells were washed 
with 2% FCS/PBS buffer and thereafter incubated for 20 min at 4°C with transcription 
factor fix/perm buffer 4X according to manufacturer’s instructions (BD Biosciences, 51-
9008100). Subsequently, fixed and permeabilized cells were washed again with perm 
wash buffer (BD Biosciences, 519008102). Cells were thereafter incubated for 20 min at 
RT with perm wash buffer containing FOXP3- PE-CF594- 259D/CY antibody (BD 
Biosciences, 562421). Cells were acquired on an LSRFortessa™ (Serial # 





3.3.4 Seq-Well assay 
Single-cell RNA-sequencing analysis was conducted using a recently developed Seq-well 
technology (21). The experimental design has been previously described by Gierahn et 
al., (21) and was conducted and analyzed with assistance from Dr. Alex Shalek’s 
laboratory. Briefly, two early treated LN samples were sorted to obtain the following cell 
subsets i.e. germinal center (GC) TFH (CD4+CXCR5hiPD-1hi) and TFR 
(CD4+CXCR5+PD-1+CD25+CD127-). Sorted cell populations were thereafter taken 
through the Seq-Well experimental and analysis pipeline (21). 
 
3.3.5 Tetramer staining 
HIV-specific CD4+ T cell responses were defined using fluorochrome-conjugated MHC 
class II tetramers as previously described in Laher et al., (22). The following antibodies 
to cell surface molecules were used: Live/dead fixable blue dead cell stain kit (Invitrogen, 
L23105), CD3-BV711-OKT3 (BioLegend, 317328), CD4-BV650-SK3 (BD 
BioSciences, 563875),  CD8 - HV500 – RPA-T8 (BD Biosciences, 560774), CXCR5-
AF488-RF8B2 (BD Biosciences, 558112), CXCR3-BV605-G025H7 (BioLegend, 
353728), CD25- PE-Cy5 -M-A251 (BD, 555433), CD127-BV785-A019D5 (BioLegend, 
351329), PD-1–BV421-EH12.2H7 (BioLegend, 329920), CCR7- PerCP-Cy5.5-T68 
(BioLegend, 335605) and CD45RA-AF700-HI100 (BioLegend, 304120). Cells were 
acquired on an LSRFortessa™ (Serial # H647794E6049, BD). Flow data was analyzed 
using FlowJo software (FlowJo, LLC version 10.1). 
3.3.6 Statistical analysis  
Statistical analysis and graphical presentation were performed using GraphPad Prism 
version 7.0 software (GraphPad Software Inc., La Jolla, CA, USA). Mann-Whitney U 
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test was utilized to compare differences between any two groups and Spearman’s Rank 
correlation was used to define the correlation between two variables. Statistical analysis 
of significance was calculated using Kruskal Wallis test with Dunn’s post hoc analyses 
for multiple comparisons. Statistical significance was set at p < 0.05. 
3.4 Results 
T regulatory cells have been shown to play a pivotal role in chronic viral infections by 
limiting immune activation and specific immune responses (23).  TFR, which was 
recently discovered in the LNs has not been well characterized and there are no well-
defined markers to distinguish it from the conventional TREGS in circulation and in the 
LN and from the TFH cells, which is the predominant CD4+ T cell subset in the LN, thus 
we sought to undertake a comprehensive phenotypic characterization of these cells. With 
access to precious LN samples for our studies, we used multi-parameter flow cytometry, 
single-cell RNA sequencing and MHC class II tetramer technologies. A total of 31 
individuals, 8 of whom were HIV negative, 16 early treated and 7 chronic untreated 
individuals were analyzed. The clinical characteristics of study participants are detailed 









Table 3.1 Summary of clinical characteristics of study participantsa 
 HIV negative Early treated Untreated 
n 8 16 7 
Age (years) 20 (19-23) 21 (18-25) 26 (24-28) 
CD4 count (cells/ul) N/A 782 (507-1248) 856 (355-1229) 
Viral load (copies/ml) N/A <20 (<20-55,000) 1900 (<20-59,000) 
a All participants were female 
 
3.4.1 Expression of CD25 and FOXP3 define regulatory T cells. 
To identify TFR, we firstly needed to define the parent population which is TREGs. There 
are however numerous definitions of this regulatory subset having been described based 
on the expression of FOXP3, CD25 and CD127. Also, various phenotypic combinations 
have been used to define these regulatory cells, these include: CD4+FOXP3+ (24, 25), 
CD4+CD25+/hiFOXP3+ (5, 26, 27), CD4+CD25+CD127low (6, 28) or 
CD4+CD25+CD127lowFOXP3+ (4, 29). To assess the similarity among these cell 
populations, we began by evaluating 8 healthy participants using flow cytometry. We 
assessed the following three phenotypes; CD4+FOXP3+, CD4+CD25+CD127- and 
CD4+FOXP3+CD25+ (Figure 3.1 A). Results showed that these phenotypes were 
interchangeable as we observed that indeed CD25+ cells overlap with FOXP3+ cells 
(Figure 3.1 B) and there was a strong correlation between CD4+CD25+CD127-, 
CD4+FOXP3+CD25+ and CD4+FOXP3+ T cells (Spearman r=0,9648; p<0,001) (Figure 
3.1 C). For our study we thus defined TREGs as CD4+FOXP3+, TFR as 
CD4+CXCR5+PD1+CD25+CD127- and TFH as CD4+ CXCR5+PD1+, but since 
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FOXP3 is an intracellular marker, it could not be used for sorting live cell populations, 
we thus defined TREGS using the CD25+CD127- phenotype while sorting these cells. 
Together these results illustrate the importance in finding a more universally utilized 





Figure 3.1. Phenotypic characterization of regulatory T cells in the lymph nodes of 
healthy donors. (A) Gating strategy for defining subsets of regulatory CD4+ T cells 
using FOXP3, CD25 and CD127. Plots shown are gated on lymphocytes, then CD3+ and 
CD4+ cell populations. (B) Representative plot demonstrating overlay of CD25+ CD127- 
populations and FOXP3+ populations together with CD25-CD127+ and FOXP3- 
populations. (C) Correlation of the frequency of CD4+CD25+CD127- and 
CD4+CD25+FOXP3+ cells (y-axis) and CD4+FOXP3+ populations (x-axis) within the 
same individuals (Spearman r = 0,9448, p <0,001).     
 
3.4.2 TFR are phenotypically different from TFH and TREGs. 
 
Having defined TREGs, we next sought to discriminate this subset from our cell subset 
of interest in this study, which are TFR. We also wanted to distinguish TFR from its 
closely linked counterpart, the TFH cells. The biology of TFR is not fully understood 
because of the difficulty in obtaining human LN samples and the lack of reliable markers 
that best defines this population. It is necessary to more clearly define this cell subset to 
better understand its biology. To understand the phenotypic differences of these 3 cell 
subsets, TREGs, TFH and TFR, we performed flow cytometry on LN and peripheral 
blood samples to assess the expression of the following canonical markers [measured as 
median fluorescence intensity (MFI)] of CXCR5, PD-1, ICOS, CD25 and FOXP3, 
markers used by other studies to define these cells. These markers of interest were chosen 
as they have been previously described as important in defining helper and regulatory T 
cells. The lymphoid homing marker, CXCR5, was expressed in comparable levels by 
TREGs, TFH and TFR in the LN, however TREGs had the lowest MFI in peripheral 
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blood (Figure 3.2 A). Both TFH and TFR cell commitment require programmed cell death 
protein-1 (PD-1) and inducible T-cell costimulatory (ICOS) amongst other transcriptional 
signaling (30). We next assessed these two co-stimulatory molecules between TREGS, 
TFH and TFR. In comparison to TREGs (p=0,0002; p=0,0002) and TFR (p=0,02; p=0,01) 
cells, TFH had the highest MFI of PD-1 in both LN and peripheral blood respectively 
(Figure 3.2 B). ICOS expression however, was highest in TFR in LNs compared to 
TREGs (p=0,003) and TFH (p=0,01), concordant with previous reports (Sage et al., 
2015). However, no difference was observed in peripheral blood (Figure 3.2 C). As 
previously described, CD25 and FOXP3 expression are known to distinguish regulatory 
subsets. Higher levels of CD25 and FOXP3 were observed on the regulatory subsets i.e. 
TREG and TFR compared to TFH which was almost negligible (Figure 3.2 D and E 
respectively). These results demonstrate that the expression of key phenotypic markers 















Figure 3.2. Immunophenotypical features of TREG, TFH and TFR in lymph nodes 
and peripheral blood of HIV uninfected individuals. Representative histograms and 
summary plots of median fluorescence intensity (MFI) values for (A) CXCR5, (B) PD-
1, (C) ICOS, (D) CD25 and (E) FOXP3 on TREGs (pink), TFH (blue) and TFR (orange). 
Statistical significance was determined using Mann–Whitney U tests.  
 
3.4.3 TFR cells are transcriptionally distinct from TFH cells. 
To further define the phenotypic and functional features of TFR and to possibly identify 
novel markers that can be used to discriminate these subsets, our next approach was to 
examine the transcriptional profiles of TFR and TFH using Seq-Well single cell RNA-
sequencing technology. Seq-Well allows for single cell capture by barcoded mRNA 
capture beads in an array of sub-nanoliter wells, enabling efficient cell lysis and transcript 
capture (21). Single cell sequencing further allows detailed and comprehensive studies of 
individual cells with a starting material from as few as 1000 cells. This technique was 
ideal for our cell of interest the TFR which is a low frequency population. The GC TFH 
and TFR were sorted from LMCs based on the phenotypic markers shown in Figure 3.3 
(A) and sequenced as described by Gierahn et al., (21). To examine the transcriptional 
profile of TFR relative to TFH we first performed principal component analysis and the 
transcriptomes of each subset were clearly distinct and grouped by subset (Figure 3.3 B). 
This was confirmed by unbiased clustering indicated by T-SNE analysis (Figure 3.3 B). 
An unbiased gene expression profiling was conducted, and we identified several distinct 
markers that were specific for the TFR subset compared to TFH cells (Figure 3.3 C). 
Specific markers like CCR7 (p=0,004), NINJ1 (p<0,0001), LTB (p<0,0001) and 
HAP1(p=0,001) were significantly expressed on TFR compared to TFH (Figure 3.3 C). 
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CCR7 has been shown to be a requirement for the in vivo functioning of CD4+ CD25+ 
regulatory T cells (31). NINJ1’s role in regulatory T cells is relatively understudied, 
however it has been shown to mediate cell communication and enhance entry, migration, 
and activity of leukocytes during developmental and inflammatory processes (32). 
Studies show that regulatory T cells use lymphotoxin beta (LTB) receptor to migrate to 
lymph nodes. This novel form of TREG migration in tissues may provide a unique target 
for modulating Treg-mediated suppression (33).  Our results demonstrate transcriptional 
signature differences between TFR and TFH which could be used for in vitro and 









Figure 3.3. Transcriptional signature of follicular T cell subsets. (A) Representative 
flow cytometry plots showing gating strategy for two sorted populations i.e. GC TFH and 
TFR. (B) Principal component analysis (PCA) and t-SNE visualization of clusters 
identified among Seq-Well LNs single-cell transcriptomes recovered from loaded arrays. 
(C) Violin plots indicating probability density of markers defining the TFR cluster (p 
values in red indicate differences between expression between GC TFH and TFR). 
 
3.4.4 Effect of HIV infection or treatment status on global TFR proportions in the 
LN and in peripheral circulation.  
 
CD4+ T cells are known to migrate to GCs and B cell follicles within secondary lymphoid 
compartments to provide help to B cells (34). Having been able to use previously 
described phenotypes to detect TREGs, we next wanted to answer the question on what 
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proportion of CD4+ T cells from within LN and peripheral blood constituted TFR, 
TREGS, or TFH. We utilized matched peripheral blood and LN from healthy participants 
to conduct this analysis. Using flow cytometry, we began by first characterizing these cell 
subsets with the following phenotypes: total TREGs (CD4+FOXP3+), total TFH 
(CD4+CXCR5+PD-1+) and total TFR (CD4+CXCR5+PD-1+CD25+CD127-) (Figure 3.4 
A). We observed that FOXP3+ cells made up only 8% of the total CD4+ T cell population 
in LN (Figure 3.4 B, panel i) and 3% of the total CD4+ T cell population in peripheral 
blood (Figure 3.4 B, panel ii). Less than 10% of total FOXP3+ cells expressed chemokine 
receptor CXCR5, the chemokine receptor required for cells to migrate into GCs (Figure 
3.4 C). The lack of CXCR5 expression on the majority of FOXP3+ cells in lymph node 
samples suggest that regulatory CD4+ T cells predominantly localize in extra-follicular 
areas of the lymph node. We next determined the global frequencies of TREGS, TFR and 
TFH subsets in HIV uninfected individuals and observed higher proportions of TFH in 
PBMC compared to TFR (p=0,002). However, no significant differences between the 
three subsets in the LN were observed (Figure 3.4 D). These results suggest that higher 
frequencies of TREG, TFR and TFR are observed in LN compared to PBMC. 
Furthermore, frequencies of TREG, TFR and TFH cells are similar in healthy donors, 
particularly in LN.  
 
Alteration in regulatory subsets and the impact of ART during HIV-1 infection have long 
been documented with conflicting reports regarding an increase or decrease in overall 
frequency of TREGs in response to infection and treatment initiation (4, 15, 24, 25, 35). 
Having identified these subsets in healthy individuals and shown that they are indeed 
distinct subsets by phenotype and transcriptional pattern, we next want to determine the 
 97 
impact of HIV-1 infection and initiation of therapy (very early) on these cell subsets. 
Using flow cytometry, we assessed changes in frequencies of total TREG, TFH and TFR 
in HIV negative individuals and compared them to HIV-infected individuals, subdivided 
into early treated and untreated. Summary plots for total TREGS (Figure 3.4 F), TFH 
(Figure 3.4 G) and TFR (Figure 3.4 H) are shown for both lymph nodes (i) and peripheral 
blood (ii). Significant increases in total TFH frequencies were observed in lymph nodes 
of early treated (p=0,04) and untreated (p=0,02) HIV infected individuals compared to 
HIV uninfected individuals (Figure 3.4 G). Total TFR and TREG cells showed no 
significant changes in both lymph nodes and peripheral blood in response to HIV 
infection or treatment initiation. These results imply, in individuals assessed, HIV 
infection and treatment initiation did not have an impact on regulatory subsets within 

















Figure 3.4. Effect of HIV infection or treatment status on global TFR proportions 
in the LN and in peripheral circulation.  Representative flow cytometry plots showing 
gating for TREGs (FOXP3+), TFH (CXCR5+PD1+) and TFR 
(CXCR5+PD1+CD25+CD127-) within CD4+ T cells. (B) Pie charts indicating 
proportions of CD4+ T cells that are FOXP3+ and FOXP3- within (i) lymph nodes and 
(ii) peripheral blood. (C) Frequency of follicular (FOXP3+CXCR5+) and non-follicular 
(FOXP3+CXCR5-) CD4+ T cells within lymph nodes and peripheral blood. Summary 
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plot showing frequencies of CD4+ T cell subsets in (D) lymph nodes and (E) peripheral 
blood. Samples from HIV negative (HIV neg), early treated (Early Tx) and untreated HIV-
infected (Un Tx) individuals were characterized by flow cytometry. (F to H) Summary 
plots of frequencies of (F) TREGS, (G) TFH and (H) TFR in ((i) lymph nodes and (ii) 
peripheral blood. Statistical significance was determined using Mann–Whitney U tests. 
 
3.4.5 Frequency of antigen-specific TFR and TREG cells decrease during ART 
treatment.  
Having demonstrated that TREG, TFR and TFH cells are distinct subsets of cells 
phenotypically and transcriptionally, we next wanted to determine whether these subsets 
exhibited functional HIV-specific responses. Despite the extensive study of “bulk” 
regulatory cell populations in the context of HIV-1 infection, there is limited data 
available on HIV-specificity of regulatory T cells and the induction of these cells in 
infected individuals. Furthermore, one of the key questions of TFR biology remaining 
unanswered is the antigen specificity of these cells. In order to screen HIV-specific 
responses within regulatory and helper populations, we utilized the MHC class II 
tetramers described in chapter 2 for the characterization of HIV-specific responses. These 
included the DRB1*11:01-Gag 41, DRB1*13:01-Gag 41, DRB1*13:01-Gag 31 and 
DRB1*03:01-Gag 41 tetramerized complexes. The same dual tetramer staining strategy 
utilizing a PE and APC double positive staining approach as in chapter 2 was used (22). 
We screened a total of 17 individuals, 3 HIV negative as controls and 14 HIV-infected 
treated or untreated individuals, matching PBMC samples were assessed for only 8 HIV 
infected donors. We were able to identify HIV-specific responses in TREG, TFH and 
TFR cells (Figure 3.5 A) in untreated infection and only HIV-specific responses in TFH 
cells during treated infection. Summary data from the analysis of 2 untreated (2 tetramers 
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used for 1 patient) and 12 treated (2 tetramers used for 1 patient) donors within our cohort 
expressing class II DRB1*11:01, DRB1*13:01 and DRB1*03:01 alleles on bulk CD4+ 
T cells are shown in Figure 3.5B.  Twelve individuals demonstrated HIV-specific CD4+ 
T cells ranging from frequencies of 0,01 to 0,42 % of total CD4+ T cell population (Figure 
3.5 B). Further analysis into the specific phenotype of these HIV-specific cells revealed 
low frequency tetramer+ TREGs (Figure 3.5 C), TFH (Figure 3.5 D) and TFR (Figure 
3.5 E). Combined, lymph node cells indicated higher frequencies of tetramer+ compared 
to peripheral blood, as did untreated individuals as compared to treated individuals as 
seen in TFH (Figure 3.5 D) (P=0,01) and TFR cells (Figure 3.5 E). Tetramer specific TFR 
and TFH were identified, with higher frequencies of tetramer specific TFH compared to 
TFR in LN suggesting that TFR do not necessarily act as a response to specific antigen 
exposure. Furthermore, tetramer specific cells were more frequently detected during 
untreated infection than in treated donors.  Together, these data demonstrate the 
advantage of using MHC class II tetramers in detecting low frequency antigen specific 






Figure 3.5. Antigen specificity of CD4+ T cell subsets using MHC Class II tetramers. 
(A) Overlay plots of dual-tetramer positive (Tet++) CD4+ T cells (red) on total TREG, 
TFH and TFR subsets in a lymph node. (B) Summary plot of total Tet ++ CD4 T+ cells 
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in lymph nodes of untreated (UN TX) and treated (TX) individuals. (C-E) Summary plots 
comparing proportions of total (C) TREGS, (D) TFH and (E) TFR Tet ++ cells to total 




Many unanswered questions related to the role of regulatory subsets in the context of 
HIV-1 immunopathogenesis remain. In the present study, we sought to identify and 
elucidate the function of the different regulatory and helper CD4+ T subsets present in 
LNs and peripheral blood in HIV uninfected and HIV infected individuals. The results 
from this study allowed for further detailed analysis of TFR present in lymph nodes as 
detailed in chapter 4 of this thesis. 
 
It is well known that molecular markers are essential tools for defining and analyzing 
subpopulations of immune cells. We utilized flow cytometry and transcriptional tools to 
identify TFR cells in lymph nodes and peripheral blood and differentiated them from 
TREGs and TFH. Identification of cellular markers that distinguish human TFR cells 
from other TREGs and from TFH cells is essential for future in vitro functional analysis. 
TFR as previously reported, despite being a distinct subset, shared transcriptional patterns 
with TFH cells, such as CXCR5 and were further distinguished by PD-1 and ICOS 
expression (36, 37). Unique transcriptional signatures identified using SeqWell will allow 
for better distinguishing of TFR as a regulatory CD4+ subset within the LN. 
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Several studies have shown increases in TREG and TFR frequency in individuals with 
chronic progressive HIV infection in circulating blood and lymphoid tissues (3, 10, 24). 
Contradictory to these various reported increases in infected individuals, others suggest 
decreased levels of TREGs (1, 3, 38). In this study we observed no significant changes in 
regulatory T cells, both TREG and TFR cells in chronic, untreated HIV infection or 
during treatment initiation, in both LN and peripheral blood. These discrepancies could 
be due to different phenotypic markers used for analysis, sample size, inconsistence in 
reporting either frequencies or absolute number and time during infection among 
numerous other parameters. Ultimately, depending on the phase of infection, TREGs 
frequency and tissue distribution change; and therefore, their impact on HIV pathogenesis 
may vary accordingly.  
 
The antigen-specificity of TFR cells has been a question of interest since their initial 
characterization. TFR cells were initially proposed to be specific for self-antigen because 
they were thought to derive exclusively from thymic-derived TREGs (7-9). In this study, 
we show low frequency of total TFR and TREG cells that are HIV-specific. This 
observance does not suggest that regulatory cells are predominantly not antigen-specific, 
rather that the specificity of these cells were not specific for the immunodominant 
peptide-MHC complex tested against. Limitations in the reagents for detecting all cells 
could be addressed by synthesis of more tetramers targeting a wider variety of 
specificities to allow for better recognition of antigen-specificity. These results also 
suggest that these regulatory subsets are much more diverse than what is currently known. 
Together, these data demonstrate the advantage of using the appropriate tools i.e. MHC 
class II tetramers in detecting low frequency antigen specific CD4+ T cell subsets. 
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Furthermore, it highlights the importance of developing additional MHC class tetramers 
with various peptide-MHC complexes, allowing for more widespread screening. 
Identification and further functional characterization of HIV-1 specific regulatory subsets 
will be important for further therapeutic and vaccine strategies aimed at targeting these 
cells in immunotherapies. 
 
The importance of the contribution of regulatory cells in HIV pathogenesis is increasingly 
recognized. Future studies that examine new and reliable phenotypical regulatory cell 
definitions, their trafficking and homing in different lymphoid tissue and the 
immunomodulatory functions of TREG subsets are fundamental to further understanding 
the role of regulatory cells in HIV pathogenesis.  
 
In conclusion, our study showed that TFR are different from TREGs and TFH by the 
expression of PD-1 and ICOS molecules, in addition to unique transcriptional markers 
such as NINJ1, LTB and HAP1. Moreover, we showed that HIV infection does not 
significantly impact this cell population, however a trend of less abundant TFR in 
untreated HIV infection was observed, with this possibly contributing to immune 
perturbations during chronic HIV infection. These results have implications in the overall 
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Chapter 4 Overview 
 
In chapter 3 of this thesis, we phenotypically, transcriptionally and functionally 
characterized TFR in lymph nodes and peripheral blood and assessed the impact of HIV 
disease on total TFR frequencies. We showed that TFR are distinct from TREGs and TFH 
and we identified low frequency antigen-specific TFR, particularly during untreated HIV 
infection.  
 
Although numerous studies have revealed that TFR cells can suppress TFH and B cells, 
the localization of this subset within the lymphoid tissues and how they modulate humoral 
immune responses remains poorly understood. To better understand the localization and 
function of TFR during treated and untreated HIV-1 infection, the studies in chapter 4 
analyzed the localization, phenotype and function of TFR in human lymph node tissues. 
The study provides further insights into the impact of very early treatment initiation on 
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Background: HIV eradication efforts have been unsuccessful mainly due to virus 
persistence in immune sanctuary sites such as germinal centers (GCs) within lymphoid 
tissues. Recent evidence suggests that these GCs contain a novel subset of regulatory T 
cells (TREGs), termed follicular regulatory T (TFR) cells. The exact function of these 
cells has yet to be fully elucidated. Most studies indicate that these cells control the 
magnitude and specificity of the GC response and they are essential for the maintenance 
of self-tolerance and immune homeostasis. However, detailed investigations are needed 
to fully understand the role of TFR cells in the overall humoral immune response and 
their contribution to viral persistence. Thus, we sought to investigate the localization of 
TFR cells during HIV infection in lymph node (LN) tissues and determine how early 
treatment impacts their functional roles. 
Methods: We analyzed 30 individuals, grouped into HIV-uninfected, HIV-infected early 
ART initiators (median of 1-day post detection of HIV) and untreated individuals, from 
a clade C HIV infection cohort in Durban, South Africa. TFR phenotype 
(CD4+CXCR5+PD-1+CD25+CD127-) and localization were defined using flow cytometry 
and immunofluorescence microscopy (IF). TFR regulatory cytokine; IL-10, and T helper 
cytokine; IL-21 were quantified using digital droplet PCR (ddPCR), and plasma 
antibodies were measured by ELISA.   
Results: TFR cell frequencies were significantly higher in LN compared to peripheral 
blood (PB) samples (p ≤ 0.0001). Very early ART initiators displayed larger proportions 
of TFR in the GC (PD-1hi) compared to HIV negative and untreated participants, who had 
a PD-1+, follicular phenotype (p=0.0001, p=0.001 respectively). This result was 
confirmed by IF (p=0.0001). Interestingly, TFR and TFH cells displayed comparable 
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levels of IL-10 and IL-21 mRNA transcripts as measured by ddPCR. Lastly, non-GC TFR 
frequencies showed a positive correlation with gp41 IgG antibodies at 12 weeks post-
infection.  
Conclusions: Together, our data show that very early ART results in increased TFR cell 
numbers in the GC, where they likely influence the GC response through interactions 
with TFH cells. Furthermore, the data suggest an additional function of TFR as “helper” 
cells as opposed to only their canonical function of immune suppression. These results 
could have implications for immunotherapeutic interventions aimed at using TFR and 
TFH cells as potential targets to induce durable antibody responses in early treated 
individuals. 
4.2 Introduction 
High affinity antibodies and overall humoral immunity is dependent on interactions 
between B cells and T follicular helper (TFH) cells in germinal centers (GCs). The CD4+ 
T cell helper function to B cells via secretion of cytokines and expression of costimulatory 
molecules is well characterized (1). The GC response is tightly regulated and requires 
adequate TFH and B cell interactions, however, the regulatory mechanisms underlying 
this process are not fully understood. Recent studies have identified a subset of regulatory 
T cells (TREGs), termed follicular regulatory T (TFR) cells, that express CXCR5, a 
follicular migratory receptor (2, 3). Much of the studies aimed at elucidating the biology 
and function of TFR cells have been conducted in murine models and peripheral blood 
(2-5), despite being first identified in human tonsils, where they were shown to control 
the magnitude of the GC response (6). Several studies suggest that although TFR 
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primarily differentiate from Foxp3+ TREG precursor cells (2, 4, 7) they display a mixed 
TFH/TREG phenotype because their transcriptional profile overlaps with TFH (3, 8, 9).  
 
Numerous studies have revealed that TFR cells have the ability to suppress TFH and B 
cells (10, 11). However, localization and function of the TFR cells is not very well 
understood (2-4, 12, 13). Importantly, determining the role TFR cells play in GC reactions 
may have implications on the design of therapeutic interventions. The impact of TREGs 
on HIV infection remains controversial and much less is known about TFR in HIV-1 
infection. Furthermore, with increasing numbers of individuals being initiated on 
antiretroviral therapy (ART) daily, the impact of ART-treatment on these regulatory cell 
subsets will provide useful information for rational design of immunotherapeutic 
innervations. The development of interventions that could manipulate immune responses 
capable of maintaining HIV suppression post ART cessation is desirable for the millions 
of individuals on life-long therapy. Studies have recently suggested a new paradigm of 
TFR cell function in the GC reaction, where they may promote the antibody response and 
even the magnitude of the GC response, rather than just having a suppressive role alone 
(14).  
 
To gain insight into the localization and function of TFR during treated and untreated 
HIV-1 infection, we analyzed the localization, phenotype and function of TFRs in human 
lymph node tissues using flow cytometry, immunofluorescence microscopy (IF), droplet 
digital PCR (ddPCR) and Ig ELISA.  These studies were conducted in a cohort of 8 HIV 




Analysis of TFR cell frequencies using flow cytometry and immunofluorescence 
microscopy within and outside of the GCs of lymph nodes revealed greater proportions 
of TFR cells where localized in the extra-follicular region. Paradoxically, early treated 
individuals displayed increased frequencies of GC TFR as compared to HIV negative 
(p=0.0001) and untreated (p=0.001) individuals, although no difference in non-GC TFR 
frequencies were observed between HIV uninfected and infected individuals, as well as 
between treatment statuses. In addition, when total TFR frequencies were assessed 
against markers of disease progression, a correlation was observed between total TFR 
frequencies and plasma viral load in HIV infected, untreated participants (p=0.004, 
r=0.95). Functional assessment of TFR and TFH, indicated comparable levels of IL-10 
and IL-21 mRNA expression between both CD4+ subsets within the lymph node. Lastly, 
further functional analysis of TFR, determined by correlations to HIV-specific antibodies 
in early treated individuals revealed that non-GC TFR frequencies correlated with plasma 
gp41 IgG antibodies. Together, these data provide further insight into the impact of very 
early treatment initiation on TFR cell frequencies and localization within lymph nodes. 
Elucidating HIV-specific CD4+ responses in lymphoid compartments will provide a 
greater understanding of the underlying mechanisms by which TFR cells exert a 
regulatory role in HIV-1 infection. 
4.3 Materials and Methods 
4.3.1 Study population 
Study participants were enrolled from the HIV Pathogenesis Programme (HPP) lymph 
node study cohort in Durban, South Africa. The lymph node study and recruitment 
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protocols were previously described in Chapter 3, section 3.3.1. In brief, excisional lymph 
node biopsies and peripheral blood samples were collected from a total of 30 participants. 
 
Inguinal, axillary or cervical lymph nodes were excised and in addition 120 ml of 
peripheral blood was obtained from study participants. Measurements of CD4 counts and 
viral loads were performed by Global Clinical and Viral laboratories (Durban, South 
Africa). Informed consent was provided by all study participants as a criterion for 
enrollment and participation in the study. The Biomedical Research Ethics (BREC) of the 
University of KwaZulu-Natal and the Institutional Review Board (IRB) of Massachusetts 
General Hospital approved this study. 
 
4.3.2 Lymph nodes and peripheral blood samples 
Excised lymph nodes were divided into two pieces; approximately 1/3 of the LN was 
fixed in 10% formal-saline (Sigma-Aldrich, St Louis, Missouri, USA) for downstream 
microscopy studies. The 1/3 formal-saline fixed tissue were paraffin embedded by Lancet 
Laboratories (Durban, South Africa). Tissue blocks were thereafter stored and cut using 
a microtome (Leica) for staining on individual slides. The remaining 2/3 was 
mechanically processed to release lymph node mononuclear cells (LMCs) as described 
by Schacker et al., (15). In brief, the macerated LN was passed through a 70uM cell 
strainer (BD, 352350) into a collection tube containing R10 media. Cells were pelleted 
and collected by centrifugation (1800 RPM, 6 minutes (min), room temperature (RT). 
Peripheral blood mononuclear cells (PBMCs) were isolated by HPPs core processing 
facility from patient blood samples by density-gradient centrifugation using Histopaque-
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1077 (Sigma-Aldrich). Lymph nodes and peripheral blood samples were obtained and 
processed on the same day and cryopreserved in liquid nitrogen.  
 
4.3.3 Viral RNA quantification in lymph node mononuclear cells 
Viral RNA was quantified using the Cobas® AmpliPrep HIV-1 test (Roche, Mannheim, 
Germany) from lysed, cryopreserved LMCs (10million cells/ml) by Global Clinical and 
Viral laboratories (Durban, South Africa) using standardized protocols.  
 
4.3.4 Flow cytometry analysis 
Freshly isolated and frozen LMCs and PBMCs were phenotypically and functionally 
characterized using multi-parameter flow cytometry. For phenotypic characterization 
experiments, fixation and permeabilization were performed using the transcription factor 
diluent buffer set (BD, 562574). Briefly, for surface staining, cells were incubated for 20 
min at RT in the dark in staining buffer [2% FCS in PBS buffer] containing the following 
antibodies: CD3-AF700-UCHT1 (BD, 557943), CD4-BV650-SK3 (BD, 563875), CD8-
PE- RPA-T8 (BD, 555367), CD62L-BV711 (BD, 565040), CD25- PE-Cy5 -M-A251 
(BD, 555433), CD127-BV785-A019D5 (BioLegend, 351329), CXCR5-AF488-RF8B2 
(BD, 558112), PD-1 – BV421-EH12.2H7 (BioLegend, 329920), CXCR3-BV605-
G025H7 (BioLegend, 353728), ICOS-AF647-C398.4A (BioLegend, 313516) and CCR7- 
PerCP-Cy5.5 – T68 (BioLegend, 335605). Cells were also stained with live/dead fixable 
aqua cell viability dye (Invitrogen, L34957). After the incubation period, cells were 
washed with 2% FCS/PBS buffer and thereafter incubated for 20 min at 4°C with 
transcription factor fix/perm buffer 4X according to manufacturer’s instructions (BD, 51-
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9008100). Subsequently, fixed and permeabilized cells were washed again with perm 
wash buffer (BD, 519008102). Cells were thereafter incubated for 20 min at RT with 
perm wash buffer containing FOXP3- PE-CF594- 259D/CY antibody (BD, 562421). 
Cells were acquired on an LSRFortessa™ (Serial # H647794E6049, BD). Flow data was 
analyzed using FlowJo software (Treestar FlowJo version 10.1). 
 
4.3.5 Immunofluorescence (IF) microscopy 
Multicolor immunofluorescence microscopy staining was conducted on 0.4 µM sections 
of formalin fixed paraffin embedded (FFPE) lymph nodes using the opal 4-colour 
fluorescent IHC kit (PerkinElmer, Waltham, MA, USA) according to manufacturer 
instructions with minor modifications. Briefly, following deparaffinization, rehydration 
and antigen retrieval, two blocking steps (2 x 10 min, RT) were performed using the Dako 
peroxidase blocking reagent (Agilent, S202386) and Bloxall block (Vector Laboratories, 
SP-6000). The slide was then washed with Flex 20X wash buffer (Dako, K800721) for 5 
min, followed by incubation with first primary antibody, BCL-6 (Dako, IR62561) for 30 
min at RT, washed with wash buffer for 5 min, thereafter probed with Opal polymer HRP 
(PerkinElmer, ARH1001EA) for 20 min at RT, washed with wash buffer twice (5 min) 
and detected using the Opal polymer 520 (10 min, RT) (PerkinElmer, FP1487). This 
procedure was repeated for the second and third antibodies CD4 (Dako, R64961) and 
FOXP3 (AbCam, ab22510) detected on Opal 570 (PerkinElmer, FP1488) and Opal 670 
(PerkinElmer, FP1489) respectively. Slides were counterstained with spectral DAPI 
(PerkinElmer, FF1490) and mounted with Dako fluorescence mounting medium (Agilent, 
S3023). Images were acquired using the Axio Observer with TissueFAXS imaging 
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software (TissueGnostics). Quantitative image analysis was conducted using TissueQuest 
(TissueGnostics).  
 
4.3.6 Droplet Digital PCR (ddPCR) 
Populations of interest i.e. GC TFH (CD4+CXCR5hiPD-1hi) and TFR 
(CD4+CXCR5+PD-1+CD25+CD127-) were sorted. Total RNA was extracted from 
sorted populations using the QIAzol Lysis Reagent (Qiagen, Cat # 79306) and RNeasy 
Mini Kit (Qiagen, Cat # 74106) as per manufacturer’s instructions, and used for cDNA 
synthesis using the iScript cDNA synthesis kit (Bio-Rad, Cat # 1708891). The cDNA was 
used as a template for IL-10 (ThermoFischer Scientific, Assay ID: Hs00961622_m1) and 
IL-21 (ThermoFischer Scientific, Assay ID: Hs00222327_m1) mRNA quantification by 
droplet digital PCR assays using pre-designed qPCR kits (ThermoFischer Scientific, 
4331182) on a FAM/MGB fluorescence.  
 
Briefly, PCR droplets were generated a using QX200 Droplet Generator (Bio-Rad) from 
a mastermix of cDNA, ddPCR supermix for probes (No dUTP) (Bio-Rad, 186-3025), 
pre-designed probes and droplet generation oil. PCR thermal cycling was conducted 
following optimized cycling conditions: an initial incubation at 95°C for 10 min, 40 
cycles of 30s at 94°C, 1 min at 60°C, followed by a final incubation at 98°C for 10 min 
and holding at 4°C until reading time. After PCR amplification, droplets were measured 
in the QX200 ddPCR Droplet Reader, and target gene copy number was analyzed using 
QuantaSoft analysis software (Bio-Rad) and recorded as mRNA copies/20μL. Absolute 
IL-10 and IL-21 mRNA counts were normalized to the expression of the housekeeping 
gene B2M (ThermoFischer Scientific, Assay ID: Hs00187842_m1). 
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4.3.7 Total and HIV-specific IgG and IgM ELISA 
Plasma HIV-specific IgG and IgM antibodies were measured by ELISA as previously 
described with minor modifications (16).  Briefly, 96 well plates (eBiosciences, Waltham 
MA, USA) were coated with either monoclonal anti mouse IgG or IgM (eBiosciences), 
(10 μg/ml in PBS, 100 μl/well) for 16 hours at 4oC. Plates were washed 3 times with wash 
buffer (0.05% Tween-20 in PBS) and incubated with blocking buffer (1% Bovine serum 
albumin in PBS, 200 μl/well, RT) for 1 hour. Plates were washed with wash buffer before 
and after incubation with dilutions of samples and standards in triplicates (100 μl/well, 2 
hours, RT). Pooled plasma samples from chronically infected HIV patients were used to 
generate the standard curves for HIV-specific IgG and IgM antibodies. Horse radish 
peroxidase conjugated secondary antibodies diluted at 1 in 5 000 in reagent diluent (1% 
BSA in PBS, 100 μl/well, 1 hour), followed by o-phenylenediamine dihydrochloride 
substrate (Sigma-Aldrich, 100 μl/well) were used to detect IgG and IgM antibodies in 
samples and standards. The reaction was stopped by the addition of 2N Sulfuric acid 
(Sigma-Aldrich) and the OD values (490 nm) were measured using a BIOTEC plate 
reader. OD values were imputed into GraphPad Prism 7.0 (GraphPad Software, La Jolla, 
California, USA) to plot standard curves and extrapolate IgG and IgM antibody 
concentrations in each sample. 
 
4.3.8 Statistical analysis 
Statistical analysis and graphical presentation were performed using GraphPad Prism 
version 7.0 software (GraphPad Software Inc., La Jolla, CA, USA). Mann-Whitney U 
test was utilized to compare differences between any two groups. Spearman’s Rank 
correlation was used to define the correlation between variables. Statistical analysis of 
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significance was calculated using Kruskal Wallis test with Dunn’s post hoc analyses for 
multiple comparisons. Statistical significance was set at p < 0.05. 
4.4 Results 
 
Follicular helper T (TFH) cells are required for GC formation and provide important 
signals to B cells needed for their differentiation and secretion of high-affinity and 
isotype-switched antibodies (1, 17). T follicular regulatory (TFR) cells are a specialized 
subset of FOXP3+ cells that have also been shown to regulate the differentiation of Ab-
secreting cells in GCs. TFR cell localization and function is not well understood, with the 
dominant paradigm being that they repress excessive TFH and B cell proliferation and 
thus could be implicated in the dysregulation of the immune response within sanctuary 
sites (18). To better characterize this immunoregulatory cell subset present in lymph 
nodes, we comprehensively investigated their phenotype, localization, association with 
markers of disease progression, response to early ART and function in the setting of HIV-
1 clade C infection using multi-parameter flow cytometry, immunofluorescence 
microscopy (IF), droplet digital PCR (ddPCR) and Ig ELISA. A total of 30 females were 









Table 4.1 Summary of clinical characteristics of study participantsab 
 
a 100% of participants were female 
b Range values are reported in parentheses under median values 
 
4.4.1 TFR cells localize outside of the GC in human lymph nodes.  
Having previously comprehensively investigated the phenotype, transcriptional profile 
and antigen-specificity of TFR in chapter 3, we next wanted to assess the localization of 
this cell subset. There have been a limited number of studies that assessed the frequency 
and location of TFR (19-21), particularly within human secondary lymphoid tissue, with 
no study having described this subset previously in African populations in the context of 
clade C HIV-1 infection. We began, by analyzing total TFR frequencies in lymph nodes 
and blood of 8 HIV uninfected and 22 HIV infected individuals. We observed that TFR 
exist at extremely low frequencies in peripheral blood compared to lymph node tissues 
(Figure 4.1 A) (p<0.0001), therefore, subsequent studies were all conducted on lymph 
node tissue samples. To determine the baseline features of this population, we began by 
using previously described phenotypic flow panel to identify GC TFH (CXCR5hiPD-1hi), 
non-GC TFH (CXCR5+ PD-1+), GC TFR (CXCR5hiPD-1hiCD25+CD127-) and non-GC 
 HIV negative Early treated Untreated 
n 8 15 7 
Male 0 0 0 































TFR (CXCR5+ PD-1+CD25+CD127-) within the CD4+ T cell population (20) (Figure 4.1 
B). We observed higher frequencies of non-GC TFR compared to GC TFR (p<0.0001) 
(Figure 4.1 D). Next, we investigated the localization of TFR within lymph node tissues 
using IF imaging, staining with CD4+FOXP3+ as previously described by Miles et al., 
(20), we determined localization within the GC by immunostaining with BCL-6 
(Baiyegunhi et al., 2018 unpublished) (Figure 4.1 C). The results showed that most of the 
TFR were outside the GCs, (p<0.0001) (Figure 4.1 E), consistent with flow cytometry 
data. These results demonstrate that TFR predominantly localized out of the B cell 





Figure 4.1 Majority of TFR localize outside of the germinal center (GC). (A) 
Proportion of TFR cells found in lymph nodes (LNs) compared to PBMC (p<0.0001). (B) 
Representative flow cytometry plots showing gating strategy for GC TFH (PD-
1hiCXCR5hi), non-GC TFH (PD-1+CXCR5+), GC TFR (PD-1hiCXCR5hiCD25+CD127-) 
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and non-GC TFR (PD1+CXCR5+CD25+CD127-) within CD4+ T cells. (C) 
Representative images of immunoflouresecntly stained LN sections from an HIV infected 
subject, LNs were stained with antibodies to BCL-6 (green), CD4 (red) and FOXP3 
(yellow). Images were scanned at x20 magnification and scale bars equal 100μm. (D) 
Flow cytometry summary plots comparing GC TFR and non-GC TFR (p<0.0001). (E) 
CD4+FOXP3+ cells were quantified in the entire LN cross-section and within GCs of 
LNs from 6 HIV uninfected and 28 HIV-infected subjects. TissueQuest (TissueGnostics, 
Vienna) was used to compute CD4+FOXP3+ density in each tissue section. p values were 
determined using Mann-Whitney U test.  
 
4.4.2 Plasma viral load correlates with TFR frequency during untreated HIV 
infection.  
To begin to delineate the role of TFR in HIV infection and how treatment modulates this 
population, we first assessed the relationship of these cells with markers of HIV disease 
progression. Previous studies have reported an inverse relationship between TREG 
frequency and CD4 cell counts (22-30), with contradictory findings. Furthermore, TREG 
frequency and plasma viral load were shown to be unrelated in some studies (25, 29, 31) 
and positively correlated in others (23, 24, 26, 28). Secondly, to clarify some of these 
apparent contradictions, particularly in lymphoid tissue, we analyzed the relationship 
between total TFR frequencies (%) with peak viral load (copies/ml) and viremia copy 
days (cumulative antigen load, calculated as area under the viral load curve) in HIV 
infected early treated individuals and plasma viral load (copies/ml) at the time of lymph 
node excision in untreated individuals and absolute CD4 count (cells/µl) in both groups. 
We observed a direct correlation between plasma viral load (copies/ml) and total TFR 
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frequencies in untreated HIV infection (p=0.004, r=0.95) (Figure 4.2 B). In contrast, the 
frequencies of total TFR in early treated individuals did not correlate with peak viral load 
(Figure 4.2 A), neither with viremia copy days (Figure 4.2 E), nor with plasma viral load 
at treatment initiation (data not shown). There was no correlation observed between TFR 
frequencies and absolute CD4 counts in either early treated (Figure 4.2 C) or untreated 
individuals (Figure 4.2 D). Our results are consistent with studies that report a positive 
relationship between regulatory T cell frequencies and plasma viral loads in chronic 







Figure 4.2 TFR frequency during untreated HIV infection correlate with plasma 
viral load. Correlation analysis between total TFR frequencies and peak viral load 
(copies/ml) (A), absolute CD4 count (C) and viremia copy days (E) in HIV infected early 
treated individuals and plasma viral load at the time of LN excision in untreated 
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individuals (B) and absolute CD4 count (D) in HIV infected untreated individuals. 
Spearman’s rank correlation used to compute P and rho (r) values.  
 
4.4.3 Increased frequencies of GC TFR during early treatment of HIV-1. 
Having observed increased frequencies of total TFR cells outside of the GC, we next 
wanted to assess if TFR localization is affected by HIV infection and therapy status. Most 
previous studies assessing the impact of ART on TREG frequencies have suggested that 
successful treatment significantly decreases or normalized TREG frequencies to similar 
levels of healthy donors (22, 24, 32). Moreover, peripheral TREG frequency was shown 
to be lower in ART-treated individuals compared to chronic, untreated individuals (33). 
To our knowledge, there are no studies that have assessed changes in TFR frequencies 
during very early ART initiation, more so in human lymph nodes. Determining the effect 
of early treatment on the preservation of regulatory CD4+ T cell populations in lymph 
nodes is important in providing insight into the impact of sustained viral suppression by 
very early therapy on immune regulation within lymphoid tissue.  
 
Using flow cytometry, we first compared TFR frequencies within the GCs (GC TFR) and 
outside of the GC (non-GC TFR) using the previously described phenotype in chapter 3 
of this thesis. We found that very early initiation of ART resulted in a significant increase 
in GC TFR frequencies compared to untreated individuals (p=0.001) as well as HIV 
negative individuals (p=0.0001) (Figure 4.3 A). Similarly, IF imaging using BCL-6 as a 
marker for the GC and CD4+FOXP3+ as TFR cells (Figure 4.3 C), revealed increased 
infiltration of TFR into GCs in very early treated individuals compared to untreated 
individuals (Figure 4.3 D) (p=0.0001). The number of GCs in HIV negative individuals 
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by IF staining were negligible to warrant comparison. No differences in non-GC TFR 
frequency was observed between HIV negative and HIV infected early treated (p=0.53) 
and untreated individuals (p=0.61) (Figure 4.3 B). We also did not find differences 
between early treated and untreated HIV infected individuals (p=0.16) (Figure 4.3 B). 
 
We next compared TFR to TFH frequencies by flow cytometry. Understanding changes 
in TFH and TFR cells during HIV infection is important because both cell types directly 
interact with cognate B cells and control antibody production, with many studies alluding 
to their role in controlling TFH function (2-5, 20). TFR and TFH phenotypes have been 
previously described (Chapter 3 of thesis). There were higher frequencies of non- GC 
TFH in HIV negative (p=0.001) (Figure 4.3 E), HIV infected early treated (p=0.003) 
(Figure 4.3 F) and chronic untreated (p=0.0006) (Figure 4.3 G) as compared to non-GC 
TFR. Moreover, early ART initiation was associated with increased GC TFR with a 
concomitant decrease in GC TFH (p=0.0004) (Figure 4.3 F). GC TFR and GC TFH 
frequencies were comparable in HIV negative (p=0.82) (Figure 4.3 E) and chronic 
untreated individuals (p=0.12) (Figure 4.3 G). To our knowledge, there have been no 
previous reports of increased TFR frequencies within the GC during very early ART 
initiation. This result warrants further exploration into the effect of very early ART 








Figure 4.3 Increased GC TFR during early treatment initiation. Summary plots 
comparing the frequencies of GC TFR (A) and non-GC TFR (B) between HIV negative 
(n=8), HIV infected early treated (n=15) and untreated (n=7) subjects. (C) Representative 
immunofluorescence images of multiplexed BCL-6, CD4 and FOXP3 for 3 each HIV 
negative, early treated and untreated LN cross-sections. (D) Summary plots comparing 
CD4+FOXP3+ density in GCs of early treated and untreated subjects (p=0.0001). (E-G) 
Summary plots indicating frequency of GC and non-GC TFR to GC and non-GC TFH for 
(E) HIV negative, (F) early treated and (G) untreated subjects. P values were determined 
using Mann-Whitney U test.  
 
4.4.4 Increased GC TFR during early treatment correlates with Gag p24 
persistence. 
Having observed increased frequencies of GC TFR in the 15 early treated individuals 
(who were detected during hyperacute HIV-1 infection and initiated treatment at a median 
of 1 day after virus detection) (Figure 4.4 A), we next wanted to investigate their role 
during early treated HIV-1 infection. We assessed various parameters including lymph 
node viral load (Figure 4.4 B), treatment duration prior to lymph node biopsy (Figure 4.4 
C), time to viremia suppression (Figure 4.4 D), Fiebig staging of participants (Figure 4.4 
E) and HIV Gagp24 density within the lymph node (Figure 4.4 F). Lymph node viral load 
was assessed, despite having previously found no relationship with peak viral load and 
TFR frequencies in early treated individuals, as data from our group has shown discordant 
HIV-1 RNA load in plasma and lymph nodes, with higher median viral loads in lymph 
node cells compared to undetectable plasma viral loads. Access to early treated 
individuals with different kinetics in terms of treatment duration, time to viremia 
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suppression and Fiebig staging allowed for detailed analysis of the observed increase in 
GC TFR frequencies. We observed no correlation of GC TFR frequency to any of these 
parameters except for HIV Gagp24 antigen density (p=0.03, r=0.82) (Figure 4.4 F). 
Immunostaining of the HIV-1 Gag p24 antigen in lymph node biopsies has been used to 
define virus persistence (34). Our group has previously shown that HIV Gag p24 persists 
long term in lymph nodes of individuals that have initiated ART soon after HIV infection 
(Baiyegunhi et al., 2018; data unpublished). These results warrant further investigation 
into molecular mechanisms that drive TFR expansion within the GC, even in the face of 





Figure 4.4 HIV p24 antigen correlates with GC TFR. (A) Kinetics of treatment 
duration across early treated participants. Correlation of GC TFR frequencies from flow 
cytometry staining and (B) LN viral load, (C) treatment duration, (D) time to viremia 
suppression and (F) HIV p24 antigen. (E) Distribution of GC TFR frequencies according 
to fiebig staging of participant upon treatment initiation. Spearman’s rank correlation 
used to compute P and rho (r) values. Comparison of fiebig staging P value was 
determined using Mann-Whitney U test.  
 
 4.4.5 TFR play a dual helper and immunoregulatory role during HIV infection. 
 
Having determined the localization and changes in TFR frequency according to disease 
and therapy status, we next wanted to assess function of these cells. We began by first 
analyzing function of TFR by cytokine secretion. We adopted droplet digital PCR 
(ddPCR) to detect IL-10 and IL-21 mRNA expression levels, due to the inability of other 
conventional methods such as flow cytometry to reliably measure these low-level 
cytokines, without manipulation or high background staining. IL-10 and IL-21 were 
chosen as they have been previously described as canonical cytokines secreted by 
regulatory subsets and T follicular helper cells respectively. IL-10 has been previously 
described as the master regulator of immunity to infection (35) and IL-21 has been shown 
to be secreted by TFH cells to provide help to B cells for the generation of affinity-
matured antibody during the GC reaction (36). The ddPCR method is based on water-oil 
emulsion droplet technology, where a 20 µl sample is fractionated into 20,000 droplets 
and PCR amplification of the template molecules occurs in each individual droplet (Bio-
Rad). The readout allows for separation of positive (for target gene) and negative 
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droplets. The technology provides an absolute count of target DNA copies per input 
sample without the need for running standard curves. We analyzed ddPCR on a total of 
17 individuals (4 HIV negative, 8 HIV-infected early treated and 5 HIV-infected chronic 
untreated) (Table 4.2). To allow for true quantification of selected subsets, we sorted three 
populations of interest i.e. double negative (CD4+CXCR5-PD-1-), GC TFH 
(CD4+CXCR5hiPD-1hi) and TFR (CD4+CXCR5+PD-1+CD25+CD127-). Due to sorting 
and sample constraints, we were unable to sort GC TFR. The expectation was that the 
double negative population would show lowest levels of each cytokine. We utilized a 
housekeeping gene, B2M (Figure 4.5 B), which is found in diploid on all human cells to 
normalize expression levels of IL-10 and IL-21 (Figure 4.5 A) and determine input cell 
number.  
 
We confirmed the production of IL-10 by TFR, interestingly, we found that they also 
produce IL-21 mRNA. Furthermore, we observed no significant differences in mRNA 
expression levels of both IL-10 (Figure 4.5 C) and IL-21 (Figure 4.5 D) between GC TFH 
and non-GC TFR. Previous work has reported that TFH cells, like TFR can produce IL-
10 (37). Intriguingly, a previous study in LCMV showed that compared to IL-21-single 
producing TFH cells, IL-10+IL-21+co-producing TFH cells exhibited an enhanced 
germinal center (GC) TFH-like profile. Additionally, IL-10-producing TFH cells have an 
increased capacity to form stable TFH-B cell conjugates compared to their IL-10− TFH 
counterparts (38). Furthermore, IL-10 secretion via TFR has been shown to promote the 
GC reaction (39). These studies suggest that TFR play a multi-faceted role in fine-tuning 
of the GC reaction. The results also suggest a role for TFH-derived IL-10 in promoting 




Figure 4.5 IL-10 and IL-21 mRNA expression. (A) Representative plots indicating 
positive IL-10/IL-21 and (B) B2M mRNA expression computed by QX200 digital droplet 
PCR machine. Threshold (pink line) manually set to stringently divide negative and 
positive droplets. (C-D) Summary plots indicating mRNA quantification of DN (double 
negative, CD4+CXCR5-PD-1-), GC TFH (CD4+CXCR5hiPD-1hi) and TFR 
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(CD4+CXCR5+iPD-1+CD25+CD127-) for IL-10 (C) and IL-21 (D) in HIV negative 
(n=4), HIV-infected early treated (n=8) and HIV-infected untreated (n=5) subjects. 
 
4.4.6 Non- GC TFR frequency in lymph nodes correlates with gp41 IgG responses.  
While it is evident that TFR play an important role in the control of antibody production, 
the question remains on whether they primarily control GC B-cell numbers or have an 
indirect role in the control of the quality and specificity of the antibody response. We next 
wanted to assess an alternate function of TFR, by determining whether TFR frequencies 
inside and outside of the GC indicated a relationship to B cell responses by production of 
HIV-specific class switched antibodies. Previous animal studies have shown that TFR 
cells were required to produce high-affinity antigen-specific Abs (9) and loss of TFR cells 
led to significantly decreased IgG responses. We analyzed non-GC TFR as well due to a 
recent study that suggested that TFR-mediated suppression is primarily mediated outside 
of the GC (21), and we assumed this would be true for “helper” functions as well. We 
measured plasma HIV-1 gp41 and gp120 glycoprotein-specific IgG and IgM titers in 
early treated individuals at 12 weeks post-infection because previous data from our group 
indicated that plasma gp41 and gp120 antibodies were induced early and peaked at 
approximately 12 weeks post-infection in these cohort of early treated individuals 
(Baiyegunhi et al., 2018; data unpublished). We observed a significant positive 
correlation between non-GC TFR frequency and gp41 IgG (Figure 4.6 F), which was not 
observed with GC TFR (Figure 4.6 B). However, we did not observe a correlation of GC 
TFR and non- GC TFR frequencies to either gp120 IgG (Figure 4.6 A and E), gp41 IgM 
(Figure 4.6 C and G) or gp120 IgM (Figure 4.6 D and H) respectively. These data suggest 
localization of TFR cells outside the GCs could be influencing gp 41 IgG production in 
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our cohort, supporting the interpretation by Sayin et al., 2018 (21), that TFR cells do not 
need to physically reside in the GC to modulate antibody production.. Furthermore, the 
magnitude of the TFR response could be a reaction to the magnitude of antibody response. 
These results could suggest that during antibody production, the role of TFR could be 






Figure 4.6 non- GC TFR frequency in LN correlates with gp41 IgG responses at 12 
weeks post infection. Correlation between frequencies of GC TFR and non-GC TFR to 
titers of gp120 IgG (A, E), gp41IgG (B), gp41 IgM (C, G) and gp120IgM (D, H) 
respectively. Titers for these antibodies were determined at 12 weeks post-infection for 
early treated individuals (n=8). Spearman’s rank correlation P and rho (r) values reported.  
4.5 Discussion 
Animal studies have shown that TFR is a specialized TREG subset which potentially 
regulates GC B and T cells during the GC reaction, however due to their relatively recent 
discovery, the role of TFR in human disease remains to be fully elucidated. In this study, 
we provide a comprehensive analysis of the localization and function of TFR cells in 
HIV-1 infection, particularly in the setting of very early treatment initiation. We show 
that despite the widely-accepted paradigm that TFR cells function within the GC, we find 
that they mostly localize in the extra-follicular region, where they likely influence the 
humoral immune response from an “outside in” concept described by Sayin et al., (21). 
This proposed concept suggests various methods by which TFR could exert their 
function. These include, preventing long-lived interactions between cognate T and B cells 
at the T-B border, which has been shown to be an important site for TFH differentiation 
(40, 41), preventing activated TFH cells from entering pre-existing GC reactions (42), or 
as widely believed, directly suppressing B cells, thus preventing differentiation into 
memory B cells, GC B cells and long-lived plasma cells (18, 19, 43).  
 
Similar to TREGs, the role of TFR on HIV pathogenesis is also unclear. Furthermore, the 
impact of prompt antigen reduction by very early ART initiation on TFR frequency, 
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function and localization has not been explored. Our data showed no significant 
differences in TFR frequencies between chronic untreated individuals as compared to 
HIV negative individuals for both GC and non-GC TFR. A similar result was observed 
in a SIV macaque model indicating an apparent reduction in TFR frequency in the lymph 
nodes during the chronic phase of infection measured both by flow cytometry and 
immunohistochemistry, which was also observed in acute infection (44). This was 
opposed to different studies that showed an expansion of TFR in both chronic HIV and 
SIV infection (20). The conflicting results pertaining to the dynamics of TFR cells might 
be due to numerous factors including sample size, sampling time points and lack of 
consensus of phenotypic markers and anatomical locations sampled (peripheral blood 
versus tissues) and differences in methods of quantification (frequencies vs absolute 
numbers) (45). All of these discrepancies contribute to a lack of consensus on the 
important roles played by regulatory cells during the course of HIV-1 infection. With 
access to a unique cohort of paired LN and peripheral blood samples, we have been able 
to shed some light on the dual role of suppressor and helper of regulatory cells within 
lymphoid tissue.  
 
Although, previous work has described the impact of ART on TREG frequencies as 
significantly decreasing or normalizing TREG frequencies to similar levels of healthy 
donors (24), we found that very early ART initiation results in increased TFR frequencies, 
particularly within the GC, this in comparison to HIV negative and chronic untreated. 
TFH cell numbers need to be well regulated in the GCs to have optimal B cell affinity 
maturation (46), with very high GC TFH cell numbers during untreated chronic HIV 
infection contributing to a dysregulated GC response (47). TFR could be playing a role 
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in this regulation. Also, a previous study from our group showed that early treated 
individuals have superior functioning TFH cells, which could be attributed to a more 
mitigated TFH response (Baiyegunhi et al., 2018, unpublished). Increased TFR 
frequencies within the GC, observed during very early ART initiation, could be 
contributing to the better functional output of TFH.  
 
There has been much discussion on the function of TFR, with literature mainly describing 
them as suppressors of the GC reaction and the antibody response. We assessed the 
function of TFR in two ways, firstly by measuring IL-10 and IL-21, canonical regulatory 
and helper cytokines respectively and secondly, by determining the relationship between 
TFR frequency and HIV-specific antibody titers. Interestingly, we found no differences 
in mRNA expression of IL-10 and IL-21 between GC TFH and TFR. As mentioned, 
consensus considers IL-10 an inhibitory cytokine, however it has been reported that TFH, 
like TFR cells, can produce IL-10 (37). Furthermore, IL-10 secretion has also been shown 
to promote and maintain the GC reaction in LCMV infection (39). IL-21 has been shown 
to be key cytokine that drive germinal center formation and antibody class switch 
recombination (Pissani et al., 2014, Morita et al., 2011), and notably IL-10+IL-21+co-
producing TFH cells have been shown to exhibit an enhanced germinal center (GC) TFH-
like profile in LCMV again (38). These results suggest that the cells within the GC, 
particularly TFR cells exert different functions under different conditions, which needs 
further exploration. Also, further studies are needed to assess the signals that drive TFR 
cells to switch between help and suppression. 
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The observation of a positive correlation between gp41 IgG titers and non-GC TFR 
frequency warrants further study. In conjunction with the view of TFR as suppressors 
more evidence is emerging that they could play a helper role. A murine model by Wu et 
al., (9) showed that the loss of TFR cells led to a significantly decreased IgG response, 
with TFR cells being required to produce the highest affinity Ag-specific antibodies. 
Furthermore, in a peanut food allergy model by Xie and Dent (14), TFR cells have been 
shown to maintain peanut-specific GC responses and IgE response. Thus, highlighting 
the key role TFR could play as novel targets for various immunotherapies.  
 
Overall, these data provide further detailed insight into the localization and function of 
TFR cells in HIV-1 infection. The study suggests a role of TFR in regulating GC TFH 
cell numbers during early treatment, which could culminate to better functioning of TFH 
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CHAPTER 5: GENERAL DISCUSSION, 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The HIV/AIDS pandemic represents one of the most important global health challenges. 
There have been tremendous advances in biomedical research and the implementation of 
effective antiretroviral treatment (ART), which enabled control of the virus resulting in 
dramatic improvement in the health and life expectancy of people living with HIV. 
Nonetheless, current treatment strategies have various limitations. Drug toxicities, 
persistent immune dysfunction, inflammation, excessive risk of co-morbidities and 
psychological issues pose important health consequences, over and above the immense 
logistical and operational challenges that come with delivering life-long care (44). These 
factors highlight the importance of identifying an effective means of controlling the virus 
in the absence of therapy. Therefore, the search for a curative strategy for HIV, together 
with finding an effective vaccine are key priorities for the future of HIV research. Despite 
the enormous challenges faced in achieving the goals of an effective vaccine and 
development of a cure, there has been significant progress made. Candidate vaccine trials 
are currently being tested (172) and the definition of a cure has shifted from finding a 
sterilizing cure to a more practical outcome of long-term remission, generally defined as 
absence of viral rebound after ART cessation, rather than complete eradication within an 
individual of all replication-competent HIV (63-65).  
 
Central to development of a cure or a preventative HIV vaccine is to improve our 
understanding of host antiviral immune responses, particularly in very important tissue 
sites. These tissues have been studied in animal models, but these models have limitations 
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such as use of animal-specific viruses, shorter duration and lower effectiveness of ART 
(173). In addition, widespread use of ART for both HIV treatment and pre-exposure 
prophylaxis has dramatically altered the direction of HIV research. Effective ART 
reverses many abnormalities caused by HIV’s profound impact on the immune system, 
however a state of persistent inflammation and immune dysfunction typically persists. 
Chronic low-level inflammation within the adaptive and innate immune systems, CD4+ 
and CD8+ T cell dysfunction, lymphoid fibrosis and elevated immunoregulatory 
responses characterize the immune state during ART (174-176). This compromised 
immune state is thought to contribute to HIV persistence, with efforts to clear the 
reservoir requiring a reversal of some or all of these immunologic abnormalities (61, 77). 
Improved understanding of immune responses in early treated individuals would be 
valuable to future HIV cure interventions or vaccination strategies.  
 
Our group is uniquely positioned to contribute to gaps in knowledge due to access to a 
hyperacute HIV infection cohort. The FRESH cohort was purposefully designed to 
identify early infection by carrying out longitudinal follow-ups and frequent testing for 
HIV acquisition in a high-risk HIV negative study population (56). Individuals identified 
in hyperacute infection are placed on ART very soon after infection, with their immune 
responses being able to be defined in peripheral blood and lymph node samples. The 
cohort is an invaluable resource in enabling longitudinal characterization of HIV-specific 




A growing body of literature has shown that effector CD4+ T cells are an important factor 
in immune control of HIV-1 infection. The role of CD4+ T cell responses in the control 
of numerous chronic viral infections has been well characterized, yet little is known about 
the role of these responses in HIV-1 infection. Previous studies have suggested that the 
preservation of HIV-1 specific CD4+ T cell responses might be critical for the control of 
viral replication (177, 178). A CD4+ T cell subset, T regulatory cells (TREGs) have been 
shown to be a key component of the immune system, to maintain the delicate balance 
between overactive responses and immunosuppression. In HIV infection, TREGs play 
both a beneficial and detrimental role (133). They regulate the immune system such that 
inflammation and spread of virus through activated T cells in suppressed. However, the 
suppression of immune activation also limits viral clearance and promotes reservoir 
formation (179). The apparent importance of TREGs in the pathogenesis and control of 
HIV makes them an interesting target for therapeutic manipulation in the search for an 
HIV cure.  
 
The majority of HIV replication occurs in secondary lymphoid organs, with HIV RNA 
particularly concentrated in B cell follicles during chronic untreated infection, prior to 
progression to AIDS (155, 158). Data during chronic HIV disease show that follicular 
CD4+ cells are approximately 30-40-fold more likely to harbor HIV RNA compared to 
extra-follicular counterparts (156, 180). A reduction in the frequency of HIV RNA+ cells 
in lymph nodes and B cell follicles is observed during ART and lymphoid architecture is 
partially restored (181). TFR have been shown to limit the GC reaction and antibody 
production to prevent autoimmunity (138). The discovery of TFR has led to a revised 
view of the regulation of anti-HIV humoral immunity. However, many questions 
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regarding their biology, localization and function remain unanswered particularly as most 
of the previous work carried out on TFR has been carried out in non-human models or 
non-tissue samples. Identifying the factors that influence TFH function during HIV 
infection would be important and could lead to improved immune reconstitution in ART-
treated individuals and potentially augment strategies to cure HIV infection.  
 
The current study comprehensively characterized regulatory cells, particularly TFR from 
lymph nodes and peripheral blood during untreated and very early treated HIV-1 clade C 
infection and defined the phenotype, localization, antigen-specificity and function of 
these cells. The study showed that TFR are important players within the controlled 
sanctuary sites of LNs and early initiation of ART changes the localization and function 
of these cells.   
 
Study implications and future directions 
Overall, these studies highlight the important contribution of CD4+ T cells to immune 
protection against HIV-1 infection. Our initial study directed at developing tools to 
identify low frequency HIV-specific CD4+ T cells in the setting of clade C infection 
demonstrated an association between the frequency of HIV-specific CD4+T cell 
responses targeting an immunodominant DRB1*11-Gag41 complex and HIV viral 
control, thus highlighting the important contribution of a single class II MHC-peptide 
complex to the immune response against HIV-1 infections. The data obtained further 
underlined the use of MHC class II tetramers as a sensitive tool for interrogating HIV-
specific CD4+ T cells responses in natural infections.  
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The rest of the investigations focused on characterizing immunoregulatory CD4+ T cells 
within peripheral blood and lymph node compartments. We identified TREGs, TFR and 
TFH cell subsets in HIV negative, HIV infected early treated and untreated individuals. 
We further used the class II tetramers developed to answer an important outstanding 
question in the field: do TREGs/TFR need to be antigen-specific to carry out their role? 
Regulatory cells, like all CD4+ T cells are able to specifically recognize antigenic 
peptides in the context of MHC class II molecules, due to a somatically-rearranged TCR. 
Conventional T helper cell activation requires specific antigen recognition by the TCR 
and it is expected that TREGs would follow this pattern (182). It has been shown that 
antigen exposure triggers the differentiation of TFR cells (141, 144). However, the signals 
that TREGs respond to in order to become TFR cells is not well understood. Studies have 
shown that TFR cells respond more strongly to self-antigens than foreign antigens (144, 
147). Although TFR cells have been found to have specificity for the immunizing antigen 
(144), another study on TCR specificity of TFH and TFR indicated that TFR cells do not 
respond well to cognate antigen after immunization (183). In our study we were able to 
detect antigen-specific (HIV) TFR, however predominantly in lymph nodes and more so 
during untreated HIV infection. There were a few limitations regarding this analysis 
including: sample size and number of tetramers tested. Future studies should include 
synthesizing MHC class II tetramers that represent majority of the test population to 
ensure wider coverage HIV-specific CD4+ T cell responses. Indeed, it would be 
important to identify the signals that drive TFR responses to the GC and ultimately what 
antigen they recognize. 
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The identification of TFR predominantly outside of the GC warrants further investigation 
on how TFR cell activity is mediated. Furthermore, the role of ART in directing TFR 
within the GC is another important observation, particularly as early treatment has been 
shown to be beneficial for improving the quality of the TFH response in our cohort. The 
key observation of comparable IL-10 secretion by TFH and TFR as well as the link 
between non-GC TFR frequencies and gp41 IgG point to the number of unanswered 
questions regarding the role of TFR in promoting GC B cell responses and the GC-
dependent high-affinity Ab response. An interesting concept of TFR being able to 
maintain a key balance between help by GC maintenance, antibody response and antibody 
affinity and suppression by controlling TFH cell numbers, GC B cell numbers and TFH 
cell cytokines (148) further highlights the complexity of these cells as well as the scope 
of knowledge that still has to be explored.  
 
Ultimately, regulatory CD4+ T cells may play a central role in shaping the HIV reservoir 
and compromising the HIV-specific immune responses. Future work should focus on 
further refining the effects of various TREG manipulation techniques on the reservoir, 
which could be used in combination with other immunotherapies. Depletion of TREGs 
has the ability to directly target a small fraction of the reservoir, reactivate the virus and 
boost cell-mediated immune responses, all of which could be a desirable strategy for cure 
research. Future studies assessing the suggested increased permissiveness of TFR (161) 
are important as their permissiveness to infection enhances the beneficial aspects of 
targeting TFR.  
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In conclusion, the results of this study give important insights into regulatory cells within 
lymph nodes; their biology, function and their role in the setting of very ART initiation. 
Our results support the notion that TFR are important in contributing to the overall 
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